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Abstract 
Poly(lactic-co-glycolic) acid nanoparticles have gained enormous interest in the recent 40 
years for their use in pharmaceutics, diagnostics and theranostics. They show numerous 
advantages, such as biodegradability and biocompatibility, ability to deliver different types 
of drugs, surface properties, which enable further modifications and possibility of 
controlled drug release. Nonetheless, poly(lactic-co-glycolic) acid nanoparticles still have 
some drawbacks, which hinder their transition from research into clinical practice. The aim 
of this study was to establish and implement protocols for preparation of poly(lactic-co-
glycolic) nanoparticles for application in drug delivery. Non-functionalized (i.e., uncoated) 
as well as chitosan- and poly(ethylene imine) functionalized (i.e., coated) nanoparticles 
were prepared and characterized with regard to their particle size and particle size 
distribution, zeta potential, surface hydrophobicity/ hydrophilicity, morphology, solid state 
properties, and cellular interactions using buccal human TR 146 cells. The rheological 
properties of poly(lactic-co-glycolic) acid nanoparticles dispersions were also determined. 
Moreover, selected formulations were freeze-dried and stability studies were conducted for 
two months. 
Poly(lactic-co-glycolic) acid nanoparticles were prepared based on emulsion-diffusion-
evaporation method. Stirring rates, homogenization set up and stabilizer concentration 
were adjusted to achieve reproducible preparation of nanoparticle formulations. 
Hydrodinamic particle size ranged from 230 nm to 330 nm. Chitosan-coated nanoparticles 
had zeta potential of ~+30 mV, poly(ethylene imine)-coated particles showed values of 
~+10 mV and uncoated nanoparticles revealed a zeta potential of ~- 5 mV. All 
formulations showed the polydispersity index smaller than 0.25. Freeze-drying of uncoated 
and poly(ethylene imine)-coated nanoparticles was successful without the use of additional 
lyo- and/or cryo-protectants. The freeze-dried formulations were stable at 2-8 °C for at 
least two months. The uncoated nanoparticles showed the highest hydrophobicity, followed 
by the poly(ethylene imine)- and chitosan-coated ones. The positively charged 
nanoparticles interacted with the cell membrane, whereas the negatively charged 
nanoparticles were internalized by the cells in vitro.  
To sum up, robust protocols were successfully established that enabled the reproducible 
preparation of uncoated and chitosan-coated poly(lactic-co-glycolic) acid nanoparticles. 
However, the protocol for preparation of poly(ethylene imine)-coated poly(lactic-co-
vii 
 
glycolic) acid nanoparticles was shown to be inefficient and should be further optimized in 
the future studies.  
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Razširjen povzetek 
Področje izdelave, vrednotenja in uporabe nanodelcev na osnovi kopolimera mlečne in 
glikolne kisline se je v preteklih 40 letih močno razvilo, saj so le-ti izkazali velik potencial 
za uporabo v biomedicini za dostavo zdravilnih učinkovin, diagnostikov in teranostikov. 
Med njihove številne prednosti med drugim spadajo: (i) biorazgradljivost in 
biokompatibilnost, (ii) ustaljene metode priprave, (iii) uporaba za dostavo različnih vrst 
zdravilnih učinkovin (hidrofobnih in hidrofilnih majhnih molekul, biomakromolekul), (iv) 
možnost dostave dveh učinkovin hkrati, (v) stabilizacija vgrajene učinkovine in njena 
zaščita pred prehitro razgradnjo (encimi, hidroliza), (vi) možnost nadzora sproščanja 
vgrajene učinkovine, (vii) možnost ciljane dostave učinkovin in (viii) številne možnosti 
funkcionalizacije površine delcev. Kljub številnim prednostim imajo takšni nanodelci 
določene pomanjkljivosti, ki še preprečujejo njihov prehod iz faze raziskav v klinično 
prakso. Med drugimi so to: (i) majhna kapaciteta za vgrajevanje učinkovin, (ii) hitra 
sprostitev velikega deleža vgrajene učinkovine (ang. initial burst release), (iii) omejena 
stabilnost disperzij nanodelcev, (iv) vprašljiva ponovljivost izdelave, (v) visoki stroški 
prenosa izdelave na proizvodno skalo in (vi) pomanjkljivo znanje o vplivu vseh procesnih 
parametrov na lastnosti pripravljenih nanodelcev.  
Namen magistrskega dela je bil razviti metodo izdelave površinsko (ne)funkcionaliziranih 
nanodelcev, ki bo zagotavljala ponovljivost izdelave ter izvesti podrobno vrednotenje 
pripravljenih nanodelcev. Izbrana metoda priprave nanodelcev na osnovi kopolimera 
mlečne in glikolne kisline je temeljila na emulzijsko-difuzijski metodi z odparevanjem 
topila. Pripravljene nefunkcionalizirane in s hitosanom oz. polietileniminom 
funkcionalizirane nanodelce smo ovrednotili z vidika njihove hidrodinamske velikosti in 
porazdelitve velikosti delcev (fotonska korelacijska spektroskopija), površinskega naboja 
(laserska Dopplerjeva anemometrija), hidrofobnosti površine (modificirana metoda z 
barvilom Rose Bengal), morfologije (vrstična elektronska mikroskopija), kristaliničnosti 
(diferenčna dinamična kalorimetrija) in interakcij s celicami in vitro (celična linija TR 
146). Poleg tega smo ovrednotili tudi reološke lastnosti disperzij nanodelcev. Pripravljene 
disperzije nanodelcev smo posušili z zamrzovanjem in izvedli dvomesečno stabilnostno 
študijo pri 2-8 °C. 
Povprečna velikost nanodelcev z nefunkcionalizirano površino je bila ~230 nm in njihov 
zeta potencial ~-5 mV. V primerjavi z njimi so bili nanodelci s funkcionalizirano površino 
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večji in so imeli pozitiven površinski naboj. Povprečna velikost nanodelcev, ki so bili 
funkcionalizirani s hitosanom, je bila ~325 nm in njihov zeta potencial ~+30 mV, medtem 
ko je bila velikost nanodelcev funkcionaliziranih s polietileniminom ~265 nm in njihov 
zeta potencial ~+10 mV. Nanodelci so bili v disperziji torej prekriti s približno 95 nm 
debelim hitosanskim oz. 35 nm debelim polietileniminskim plaščem, ki sta rahlo negativen 
začetni površinski naboj spremenila v pozitivnega. Polidisperzni indeks vseh končnih 
formulacij nanodelcev je bil manjši od 0,25. Pripravljene disperzije nanodelcev smo 
posušili z zamrzovanjem brez uporabe dodatnih pomožnih snovi. Posušene formulacije s 
hitosanom funkcionaliziranih nanodelcev se ni dalo uspešno redispergirati, medtem ko so 
bili povprečna velikost nanodelcev, njihova polidisperznost in zeta potencial preostalih 
dveh formulacij po redispergiranju liofilizata praktično nespremenjeni glede na njihove 
lastnosti pred sušenjem z zamrzovanjem. Vsi liofilizirani vzorci so bili stabilni (z ozirom 
na hidrodinamsko velikost, širino porazdelitve velikosti in površinski naboj po 
redispergiranju) dva meseca pri temperaturi 2-8 °C . Metoda določanja površinske 
hidrofobnosti je pokazala, da so bili najbolj hidrofobni nanodelci z nefunkcionalizirano 
površino, sledili so jim s polietileniminom funkcionalizirani in nato s hitosanom 
funkcionalizirani nanodelci. Osnovni kopolimer mlečne in glikolne kisline je bil manj 
hidrofoben v primerjavi z nanodelci. Modificiran protokol z barvilom Rose Bengal se je 
izkazal kot ustrezen za vrednotenje hidrofobnih (in rahlo hidrofilnih) površin oz. 
materialov, medtem ko ni bil ustrezen za vrednotenje izrazito hidrofilnih površin oz. 
materialov (npr. hitosana in polietilenimina). Zaradi premika absorpcijskega maksimuma 
uporabljenega barvila k višjim valovnim dolžinam ob prisotnosti hitosana ali 
polietilenimina, smo pri določanju hidrofobnosti uvedli dodaten korekcijski faktor, ki se je 
izkazal kot ustrezna rešitev za izračun končnih rezultatov preskusa. Reološke meritve 
kinematične viskoznosti in strižnega modula disperzij nanodelcev, ki smo jih primerjali z 
meritvami disperzij nanodelcev s funkcionalizirano površino in odgovarjajočih raztopin 
polimerov (hitosana ali polietilenimina), so pokazale, da se viskoznost disperzije s 
hitosanom funkcionaliziranih nanodelcev razlikuje od viskoznosti raztopine hitosana, 
medtem ko se viskoznost s polietileniminom funkcionaliziranih nanodelcev od viskoznosti 
raztopine polietilenimina občutno ne razlikuje. Na slikah, posnetih z vrstičnim 
elektronskim mikroskopom, smo opazili mostičke med nanodelci. Le-ti so bili najbolj 
opazni pri s hitosanom funkcionaliziranih nanodelcih, ki so bili na sliki enakomerno 
razporejeni, medtem ko te pravilne ureditve ni bilo vidne pri ostalih dveh vzorcih 
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nanodelcev. Velikost nanodelcev na mikroskopskih slikah je bila rahlo manjša od tiste, 
določene s fotonsko lasersko spektroskopijo, opazili pa smo tudi porozne strukture 
velikosti ~300-400 nm v vzorcu s polietileniminom funkcionaliziranih nanodelcev, ki bi 
glede na dodatne eksperimente lahko bile posledica samozdruževanja presežnega 
polietilenimina in stabilizatorja v vodni fazi. Pri termični analizi smo opazili, da so imele 
vse formulacije nanodelcev podoben endotermni vrh, ki pa je bil pri rahlo nižji temperaturi 
kot vrh čistega kopolimera mlečne in glikolne kisline, kar je najbrž posledica zmanjšanja 
velikosti delcev v nano-območje in primesi drugih polimerov, ki smo jih uporabili pri 
pripravi nanodelcev. Negativno nabiti nanodelci so v velikem obsegu prešli v notranjost 
celic, medtem ko so pozitivno nabiti tvorili interakcije s celično membrano in so v celice 
vstopili v manjšem obsegu. S hitosanom funkcionalizirani nanodelci so se značilno 
adsorbirali na celično membrano, medtem ko je bilo adsorbiranih delcev v primeru s 
polietileniminom funkcionaliziranih nanodelcev na celični membrani malo. 
V okviru magistrske naloge smo uspešno razvili protokol za pripravo nefunkcionaliziranih 
in s hitosanom funkcionaliziranih nanodelcev na osnovi kopolimera mlečne in glikolne 
kisline, medtem ko končna metoda izdelave s polietileniminom funkcionaliziranih 
nanodelcev ni omogočila želene funkcionalizacije nanodelcev. Lastnosti s 
polietileniminom funkcionaliziranih nanodelcev so bile podobne lastnostim 
nefunkcionaliziranih nanodelcev (podobna hidrodinamska velikost, relativno velika 
hidrofobnost površine, podobna morfologija nanodelcev). Na osnovi preostalih rezultatov 
tj. podobnih reoloških lastnosti disperzije z raztopino polietilenimina in manj izrazitih 
interakcij s celičnimi membranami v primerjavi s hitosanom funkcionaliziranimi nanodelci 
lahko zaključimo, da je bila priprava s polietileniminom funkcionaliziranih nanodelcev 
manj uspešna. V prihodnje bi bilo zato vsekakor treba optimizirati metodo izdelave s 
polietileniminom funkcionaliziranih nanodelcev ter proučiti uporabnost dodatnih 
pomožnih snovi (lio- in/ali krioprotektantov) v procesu sušenja s hitosanom 
funkcionaliziranih nanodelcev, ki bi omogočile učinkovito redispergiranje po sušenju z 
zamrzovanjem. V prihodnosti bi bilo treba izvesti še druge raziskave, ki bi lahko 
omogočile prehod pripravljenih formulacij nanodelcev iz raziskav v klinično prakso. Med 
drugim bi bilo treba izvesti raziskave stabilnosti pri različnih pogojih in v različnih oblikah 
(npr. liofilizati, disperzije nanodelcev,…), določiti kapaciteto za vgrajevanje zdravilnih 
učinkovin, ovrednotiti profil sproščanja vgrajene zdravilne učinkovine, izvesti dodatne 
xi 
 
raziskave interakcij z drugimi vrstami celic, proučiti njihovo obnašanje in vivo in določiti 
potencialne lastnosti prodiranja skozi mukus pripravljenih nanodelcev s funkcionalizirano 
površino.  
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1. Introduction 
In the last decades new techniques, such as scanning tunnelling microscopy and atomic 
force microscopy, enabled scientists to observe structures on the nanoscale. Those so-
called “nanomaterials” may exhibit unique properties due to their size and are therefore 
attractive objects of researches. Nanomaterials are defined by The European Commission 
as “materials with any external dimension in the nanoscale or having internal structure or 
surface structure in the nanoscale (where the term “nanoscale” is defined as size range 
from approximately 1 nm to 100 nm)” (1). Showing enormous potential in broad spectra of 
applications, these materials are also attractive in the medical field, e.g. to be used in 
diagnostics, regenerative medicine, drug delivery and theranostics. While the European 
Medicines Agency (EMA) defines “nanotechnology” as “the production and application 
of structures, devices and systems by controlling the shape and size of materials at 
nanometer scale (which comprehends the size range already described)” and the term 
“nanomedicine” as “application of nanotechnology in view of making a medical diagnosis 
or treating or preventing diseases” (additionally “it exploits the improved and often novel 
physical, chemical and biological properties of materials at nanometre scale”) (2). 
Due to the promising properties of nanomaterials, a large number of studies dealing with 
the development of novel carrier-systems for drug delivery to the site of action have been 
performed. Among other types of nanomaterials, polymeric nanoparticles have gained 
increased attention. The definition of polymeric nanoparticles has not been unified by the 
research groups all over the world yet. The aforementioned definition of nanomaterials 
given by The European Commission gives some guidance, nevertheless, research groups 
tend to define polymeric nanoparticles as “solid spherical structures typically with 
diameter from 100 nm to 250 nm (3) (or with diameter less than 1 μm (4)), which can be 
prepared from natural or synthetic polymers”. In general there are two basic types of 
(polymeric) nanoparticles for drug delivery – nanospheres and nanocapsules (Figure 1). 
While nanospheres exhibit matrix structure where polymer and drug are dispersed 
uniformly in the whole volume of the nanoparticle, nanocapsules exhibit core-shell 
morphology, where a drug is entrapped in the core (3, 5). 
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To prepare either nanospheres or nanocapsules, natural polymers (e.g. chitosan, 
hyaluronan, proteins) or synthetic polymers (e.g. poly(lactic-co-glycolic) acid (PLGA), 
polylactic acid (PLA), polyglycolic acid (PGA), poly(methylmethacrylate), 
polycaprolactone) can be used (4, 5, 6). Due to variations in the properties and purity of 
natural polymers, synthetic polymers with more controlled properties are most commonly 
used (4, 6). PLGA nanoparticles (PNPs) are biocompatible and biodegradable. Therefore 
they have proved to be advantageous for solubilizing poorly soluble drugs, controlling 
their release and protecting them from preterm degradation (3, 6, 7). Moreover, they can be 
produced by simple methods. 
In the following chapters the current state of the art in the field of PNPs is described, 
ranging from the initial polymer to the characterization of the final formulation. 
1.1. Poly(lactic-co-glycolic) acid 
PLGA is a synthetic thermoplastic aliphatic polyester (8). It is a copolymer of PLA and 
PGA, which are linked via ester bond (Figure 2) (9). This can be achieved by either 
(poly)esterification reaction of glycolic and lactic acid or catalysed (poly)esterification of 
cyclic dimers of glycolic and lactic acid (7). One of the most important characteristics of 
this copolymer is the ratio between PLA and PGA in the polymer molecule. The ratio can 
Figure 1. Schematic illustration of a nanocapsule and a nanosphere adapted from F. Danhier et al. (3). 
Figure 2. Structural formula of PLGA;                                                                            
x is the number of lactic acid units and y is the number of glycolic acid units. 
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vary and thus strongly influence the physico-chemical properties of the polymer, such as 
degree of crystallinity, glass transition temperature, mechanical strength, swelling 
behaviour, degradation rate, and hydrophobicity of the polymer (7). 
PLGA exhibits partially crystalline structure, since PGA is highly crystalline, while PLA is 
just partially crystalline (i.e., poly-D-lactic acid is crystalline and poly-L-lactic acid is 
amorphous, but they are generally present in the same ratio in PLA) (6). Thus, its 
properties strongly depend on the ratio between PGA and PLA, having more crystalline 
structure with higher amounts of PGA in the copolymer. It is known that the glass 
transition temperature of PLGA usually ranges from 45 °C to 55 °C (7) and decreases with 
an increase of PGA in the polymer and decrease in its molecular weight (10). 
The ratio between PGA and PLA determines the hydrophobicity of PLGA and thus also its 
solubility. PLGA is a hydrophobic polymer, soluble in various organic solvents (e.g. 
tetrahydrofuran, acetone, dichloromethane, chloroform, ethyl acetate, hexafluoro-
isopropanol, benzyl alcohol, propylene carbonate) (4, 7, 9). Due to additional methyl 
functional groups present in PLA, it is more hydrophobic than PGA (Figure 3). Therefore, 
with increasing content of PGA in PLGA, it becomes less hydrophobic, and vice versa (9). 
This further influences the degradation rate of the polymer as well as of PNPs. 
PLGA undergoes complete hydrolysis in aqueous medium, which is catalysed by basic or 
acidic conditions. The final degradation products are non-toxic monomers of glycolic and 
(D- or L-)lactic acid. After degradation of PLGA in human body, both final products can 
be excreted directly via the kidneys (6, 8). Additionally, glycolic acid and L-lactic acid can 
be metabolized further via Krebs cycle into carbon dioxide and water (9). This results in 
low systemic toxicity of PLGA. The degradation rate is further increased by the acidic 
degradation products of PLGA, which cause autocatalysis of the hydrolysis. With the 
variation in the ratio between PGA and PLA, the degradation time of PLGA can vary from 
several months to several years (being also influenced by the molecular weight of the 
Figure 3. Structural formula of PGA (left) and PLA (right);                             
n is the number of monomer units. 
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polymer) (3, 9). With lower molecular weight of the polymer and higher PGA content, the 
degradation rate increases, and vice versa (9, 11). This is due to the fact that increased 
PGA content results in more hydrophilic properties of the polymer. The water, which is 
needed for the hydrolysis of the polymer, is adsorbed in larger amounts accelerating its 
degradation rate. However, the fastest degradation rate has been reported for PLGA, 
consisting of PGA and PLA in the ratio 50:50 (6). In case of degradation of PNPs, surface 
to volume ratio has to be considered as it influences the degradation rate of PNPs. It is 
known that degradation of the polymer is faster in the core of the PNPs compared to the 
surface, thus the polymer undergoes the bulk degradation instead of more usual surface 
degradation (9). Other factors that influence the polymer and PNPs degradation rate are (i) 
the pH value of the medium, (ii) the amount and type of drug loaded, (iii) the temperature 
of the environment and (iv) surface modification of polymeric nanoparticles (7, 9). The 
role of enzymes in the biodegradation of PLGA is still unknown (6). 
1.2.  PNPs preparation methods  
The selection of the preparation method for PNP preparation is of high importance, 
because it can strongly influence the final characteristics of PNPs, e.g., shape, size, size 
distribution, stability, and drug release kinetics, which can be of high importance for 
achieving an optimal therapeutic effect (8). Moreover, the properties of the drug and the 
PLGA polymer used have to be taken into account, when selecting an optimal preparation 
method (5). 
PNPs for medical application have been established for about 40 years; therefore, a wide 
range of preparation methods is currently available. All known preparation methods are 
based on one common process, i.e. precipitation of the polymer, which occurs due to 
decrease in the polymer solubility (5). The preparation methods can be classified into two 
groups: (i) the methods based on the polymerization of the monomers and (ii) the methods 
based on the preformed polymers (5). The methods from the first group may be associated 
with toxic residues of the polymerization (e.g. monomers and initiators), hence, these 
methods are not frequently used (5). Therefore, only the second group of methods are 
discussed in the scope of this study. They can be classified into two subgroups: 
(i) Two-step procedures, where an emulsion system is prepared first, followed by the 
formation of PNPs in the second step (e.g., emulsification-solvent evaporation method, 
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emulsification-solvent diffusion method, salting-out method, spray-drying, 
microfluidics-assisted method, phase inversion nanoencapsulation). 
(ii) One-step procedures, where the process does not require the emulsification step (e.g., 
nanoprecipitation, dialysis, coacervation, microfluidics-assisted method, supercritical 
fluid technology) (4, 5, 8). 
Because a detailed review of all above-mentioned methods exceeds the frame of this work, 
only the two most commonly used methods are described, which are important also for 
further understanding and discussion on this work. They both belong to the group of two-
step procedures, namely (i) the emulsification-solvent evaporation and (ii) emulsification-
solvent diffusion method (3). 
1.2.1. The emulsification-solvent evaporation method 
It is based on the preparation of a PLGA solution in volatile organic solvent (e.g. 
dichloromethane, chloroform) that is subsequently added to a continuously stirred aqueous 
solution of stabilizer (e.g., poly(vinyl alcohol) (PVA), polysorbate 80, vitamin E TPGS (d-
α-tocopherol polyethylene glycol succinate), poloxamer 188) to produce a stable emulsion. 
Next, the organic solvent is evaporated either at room temperature with overnight magnetic 
stirring or under reduced pressure (9). Although this method can be time consuming and 
expensive, the main advantage is the suitability to change polymer concentrations to obtain 
nanoparticles of different sizes and in different concentrations. 
1.2.2. The emulsification-solvent diffusion method  
It is based on the emulsification of a PLGA solution (e.g. in ethyl acetate) in an aqueous 
solution of stabilizer with the use of high-speed homogenizer. Next, water is added while 
stirring the emulsion in order to cause the diffusion of organic solvent from the internal 
phase, being partially miscible with water. This leads to the formation of PNPs by 
precipitation. Finally, the organic solvent is removed by either evaporation at room 
conditions or under reduced pressure (9). Compared to the above described method, the 
advantages are high batch-to-batch reproducibility, high yields, ease of scale-up, simplicity 
and narrow size distribution of the produced PNPs. On the other hand there are some 
limitations such as the high volume of the water that needs to be removed from the final 
suspension and the limit in the use of variable polymer concentrations (i.e. polymer 
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concentrations cannot be changed in wide range), which makes this method not suitable for 
preparation of PNPs with sizes below 200 nm (5, 7, 9). 
Regardless to the method used, the prepared dispersion of PNPs is usually firstly purified 
by filtration, centrifugation or dialysis and then dried to overcome its poor physical and/or 
chemical stability. For this purpose, the most commonly used method is freeze-drying (5), 
during which the use of cryo- and lyo-protectants is recommended to prevent potential 
instability of PNPs during this process (5, 12). 
1.3. Surface modification of PNPs 
The above mentioned methods enable the preparation of so-called “bare” or “uncoated” 
PNPs. The new discoveries and approaches in therapy and diagnostics have revealed the 
need of surface modification or so-called “functionalization” of PNPs. There are several 
goals, which can be achieved by surface modification of PNPs, including higher stability, 
increased residence times at a respective biological target site, improved pharmacokinetics, 
targeted drug delivery, controlled drug release and others (4, 7, 8, 9, 13, 14, 15). 
Surface modification of PNPs plays an important role in designing particles with ability to 
escape the natural defence system of human body after application (9). As PNPs are being 
removed from the blood-stream by the reticuloendothelial system (RES), achieving long 
circulation times of PNPs and thus enabling targeted drug delivery has become one of the 
most important challenges (9). Briefly, after i.v. application of PNPs, opsonins, which are 
present in blood, bind to the nanoparticle surface. Those PNPs-protein complexes are 
further attached to macrophages, where they are internalized by phagocytosis, and finally 
cleared from the body via the renal system (9). Hydrophobic PNPs are opsonized 
preferentially (9). Thus, it has been shown that modification of the PNP surface can 
significantly increase their blood-circulation time (14). In order to assure more hydrophilic 
properties of the PNP surface (and therefore prolong their circulation time in the human 
body), numerous surface modifiers, referred also as coatings, have been used (e.g. 
polyethylene glycol (PEG), poloxamers, poloxamines, chitosan, poly(ethylene imine) 
(PEI), polysorbates, poly(vinyl alcohol) (PVA), vitamin E TPGS (d-α-tocopherol 
polyethylene glycol succinate), polysaccharides (e.g. dextran), polyethylene oxide, red 
blood cell membranes and others) (4, 7, 8, 13, 15). Commonly used coatings include also 
lipids and inorganic materials (e.g. silica, silver-gold nanoparticles) (15). 
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Another important goal of surface modification of PNPs is achieving targeted drug 
delivery (TDD). TDD aims to reduce unwanted side effects of the drug, decrease the 
frequency of drug application, improve patient compliance, improve patient’s quality of 
life and improve the therapeutic outcome. In recent years a wide spectrum of approaches 
aiming to achieve TDD has been suggested. 
Although targeting of different cells, tissues or organs is possible, most attention has been 
given to the targeting of tumour cells. There are two basic principles of TDD: (i) passive 
targeting and (ii) active targeting. The first relies on the so-called “enhanced permeability 
and retention effect (EPR)”. Tumour blood vessels usually have abnormalities in their 
structure (e.g., pericyte deficiency, high proportion of endothelial cell proliferation and 
abnormal basement membrane), which lead to enhanced vascular permeability. Therefore, 
PNPs in the size range from 20 nm to 200 nm can distribute from the blood vessels into the 
tumour tissue and accumulate inside the tumour interstitial space. Moreover, the lack of 
lymphatic vessels or their functionality contributes to hindered drainage from the tumour 
tissue, resulting in so called enhanced retention of the accumulated PNPs (13). On the 
other hand, the active targeting is based on the surface modification of PNPs with targeting 
ligands, which bind to specific receptors, usually overexpressed, at the targeted site (e.g., 
tumour cells or tumour vasculature) (13). Most commonly used targeting ligands are 
biotin, folic acid, aptamers, antibodies and their fragments, peptides and lectins (8, 13). 
The main goal of surface modification of PNPs is to achieve prolonged circulation time of 
PNPs in the human body. This can be associated with controlled drug delivery and 
distribution to the site of action. On the other hand, the use of targeting ligands can cause 
also the opposite effects, i.e., decreased circulation time, due to increased opsonisation and 
removal of PNPs from the blood stream by RES (8). Moreover, the targeting ligands may 
enlarge the overall size of PNPs and therefore reduce their ability to cross biological 
barriers (8). Thus, it is of crucial importance to understand the influence of the coating 
and/or targeting ligands, attached to the PNP surface, on the particle characteristics and 
their behaviour in biological environment. 
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1.4. Characterization methods for PNPs 
The characterization of PNPs after preparation is of utmost importance to ensure well 
characterised formulation with desired properties for further application. A broad spectrum 
of different PNP properties has to be considered during characterization. Four of the most 
important properties for PNPs application in biomedicine are: (i) size, (ii) drug 
encapsulation efficiency and drug loading, (iii) surface charge and (iv) drug release profile 
(4). It is nevertheless important to mention that numerous characteristics of PNPs are 
interdependent, thus, it is important to consider as many parameters as possible to develop 
an optimal, well defined formulation of PNPs. The most important PNP characteristics are 
summarized in Figure 4. 
(Average) particle size (d), particle size distribution (expressed as polydispersity index – 
PDI) and surface charge (expressed as zeta potential ()) are the most important 
parameters, which should be investigated during formulation design and at the end of the 
formulation process (e.g., after dispersion of freeze-dried PNPs) in order to evaluate 
formulation stability and reproducibility. Hydrodynamic particle size and particle size 
distribution are most commonly measured with dynamic light scattering (also known as 
photon correlation spectroscopy (PCS)). Additionally, particle size and particle size 
distribution can be determined by nanoparticle tracking analysis (5) and imaging 
techniques, such as transmission electron microscopy, scanning electron microscopy 
Figure 4. The most important characteristics of PNPs. 
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(SEM) and atomic force microscopy. The latter imaging techniques can be applied also 
for characterization of PNPs’ morphology. Zeta potential can be determined by laser 
Doppler anemometry (LDA). According to some researchers the zeta potential can 
correlate with PNP stability (4), taking into account that stable nanoparticle formulations 
(being stabilized only electrostatically) should exhibit an absolute zeta potential value 
above 30 mV (5). 
As already mentioned, surface properties, including surface chemistry, of the PNPs can 
play an important role in their biodistribution and consequently, in drug delivery. One of 
the surface parameters already mentioned is the zeta potential, which is not just a measure 
of PNP stability, but enables also estimation of the efficiency of surface modification (e.g., 
coating with positively charged polymers like chitosan or PEI) (3). Surface properties can 
be determined by different techniques such as X-ray photoelectron spectroscopy, 
Fourier transform infrared spectroscopy, nuclear magnetic resonance spectroscopy, 
Raman spectroscopy, small angle neutron scattering, UV spectroscopy and energy 
dispersive spectroscopy (5, 13). Another surface property, which has not been studied 
thoroughly yet, is surface hydrophobicity/hydrophilicity. It is a crucial parameter affecting 
PNP bioavailability, transport in biological environment and toxicity. However, currently 
there is a lack of established methods for its determination. Until now, adsorption of 
hydrophobic dyes, contact angle measurements, shake-flask method (16), reverse 
phase liquid chromatography and hydrophobic interaction liquid chromatography 
have been investigated (13). 
It is also important to understand the solid state properties of PNPs, more precisely 
whether they are crystalline or amorphous and if the solid state characteristics have been 
changed during the preparation process compared to initial state of the polymer (and the 
drug). This can be examined with e.g., small-angle X-ray scattering or differential 
scanning calorimetry (DSC), which provide information about the interactions between 
the components in the PNPs (i.e, polymer-drug interactions) (5). 
Furthermore, drug loading, drug entrapment efficiency, and drug release kinetics need to 
be evaluated. PNPs usually exhibit high drug entrapment efficiency, which increases with 
increasing size of NPs (4). However, a big disadvantage is their limited drug loading 
capacity. To measure drug loading and drug entrapment efficiency PNPs should be treated 
to release the drug, which can be achieved by ultrasonication, heating, dissolution in 
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suitable medium, etc.. The drug released is measured with analytical methods, such as 
high-pressure liquid chromatography, UV spectroscopy, gas chromatography and 
others. To study in vitro drug release kinetics, samples are usually incubated in the medium 
resembling biological conditions (e.g. temperature, pH value). The drug released is 
measured by the above-mentioned analytical methods. To separate released and unreleased 
drug before the measurement procedures often used to separate nanoparticles from medium 
are filtration with special filters (i.e., Amicon®Ultra centrifugal filters) or 
ultracentrifugation. The drug released is than determined in filtrate or supernatant.  
It is well known that duration of drug release from PNPs can vary from hours to several 
months (13). Until now, different mechanisms of drug release have been assigned to PNPs. 
According to Kumari et al. five mechanisms of drug release are to be considered: (i) 
desorption of the drug bound to the surface of PNPs, (ii) diffusion of the drug through the 
polymer matrix of the PNPs, (iii) diffusion of the drug through the polymer shell of 
polymer nanocapsules, (iv) matrix erosion of the PNPs and (v) a combination of diffusion 
and erosion processes (17). Usually, drug release is a combination of more than one of the 
above mentioned mechanisms (9). PEGylation of the PNPs on one side increases their 
circulation time in human body (i.e. improves their pharmacokinetics), but on the other 
hand it results in accelerated drug release (18). Notably, all drug release profiles from 
PNPs show high initial burst release (3). 
Another important aspect is the stability of PNPs over time. Parameters, which enable 
tracking of physical stability of PNPs, are hydrodynamic particle size, particle size 
distribution and zeta potential. The stability of freeze-dried samples can be studied with the 
same techniques, using the re-dispersed freeze-dried samples. 
Biological aspects of PNPs to be considered are their interactions with cells, toxicity and in 
vivo biodistribution and pharmacokinetics. 
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Considering the interactions with cells, it was shown that PNPs are internalized into cells 
via two different pathways: (i) mainly via liquid phase 
pinocytosis and (ii) via clathrin-mediated endocytosis 
(13). Numerous toxicity studies have been carried out 
using a broad spectrum of cell lines, including Caco-2, 
Colo 205 and MDBK cells. They showed little or no 
toxicity of PNPs in vitro (7). Toxicity assay on visceral 
organs (e.g. spleen, liver, kidney, brain and intestine) in 
vivo was conducted after oral exposure of rats to PNPs 
and showed minimal (on liver and intestine) or no 
toxicity over a time period of 7 days (7).  
Regarding the biodistribution of PNPs it was shown that 
quickly after i.v. administration they accumulate in bone 
marrow, lymph nodes, liver, peritoneal macrophages and 
spleen. PNPs biodistribution and pharmacokinetic profile 
is assumed to be dose-dependent and non-linear (19). It is 
known that although PNPs are taken up by the spleen, 
liver and other parts of the RES, they show great 
potential to “escape” RES, if they exhibit hydrophilic 
surface and are smaller than 100 nm (13).  
It is important to stress out that in the last decade a large 
number of characterization methods have been developed 
for PNPs, however, no standardized methods or 
regulatory protocols are available currently for the 
characterization of PNPs (5). 
1.5. Advantages and disadvantages of PNPs 
PNPs show a large number of advantages, which are 
presented in Figure 5. Two of the most important benefits 
are biodegradability and biocompatibility (6), which have 
been already discussed in details in chapter 1.1.. These 
are important reasons why PLGA-based drug delivery systems for parenteral 
Figure 5. Advantages of PNPs. 
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administration have been approved by US Food and Drug Administration (FDA) and EMA 
(3). Moreover, PLGA is commercially available in different forms, i.e. with tuneable 
properties for specific final formulations (e.g. degradation time of polymer) (3). 
A number of methods for PNP preparation is currently well known, however, they enable 
further development and modifications (3). PNPs can deliver different types of drugs such 
as small hydrophobic and hydrophilic molecules (e.g. paclitaxel, 9- nitrocamptothecin, 
cisplatin, haloperidol, estradiol (3)), biomacromolecules (vaccines, genes, peptides, 
monoclonal antibodies, growth factors, DNA or RNA) and imaging agents (7). Even dual-
drug delivery systems can be prepared (15). PNPs are not only able to carry different types 
of drugs, but also enhance their stability and protect them from premature enzymatic or 
hydrolytic degradation in vivo and thus consequently, maintain their activity and integrity 
(3). With the selection of appropriate PLGA polymer, controlled drug release can be 
achieved, which can vary from hours to several months (13). This also includes sustained 
drug release and pulsatile drug release (13). Further, PNPs can be used in therapy or in 
diagnostics (imaging) or both, also known as theranostics (5). 
The possibility of surface modification of PNPs is also an important advantage. Through 
modifications, targeted drug delivery to specific organs, tissues or cells can be achieved or 
interactions with the biological environment can be improved or prevented. For example, it 
has been shown that positively charged surface modified PNPs escape from lysosomes or 
interact strongly with cell membranes via ionic interactions (3). The surface modification 
can also provide stealth properties of the PNPs (3). PNPs coated with hydrophilic 
molecules (e.g. PEG, poloxamines, poloxamers, chitosan) are invisible to the RES, thus, 
their circulation time is prolonged. 
Another interesting advantage of PNPs is the possibility to avoid first pass metabolism of a 
drug after oral administration due to absorption of PNPs via M cells present on Peyer’s 
patches and isolated follicles of the gut-associated lymphoid tissue (9). With this approach, 
the bioavailability of a drug can be significantly increased. It is also believed that surface 
modifications with PEG further facilitates this transport route and improves bioavailability 
of the drug (20).  
On the other hand PNPs show some disadvantages, which are currently limiting factors for 
their use in clinical practice or their entry into clinical trials. Two of the most important 
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ones, which have already been mentioned, are poor drug loading and high initial burst drug 
release. 
Although the encapsulation efficiency is usually high, 
PNPs show a drug loading capacity of only about 1% 
(w/w) (3). Thus, frequent application of such 
formulation (or bigger doses) is needed to achieve 
therapeutic drug dose, decreasing patient compliance. 
The high initial burst drug release, which is described 
for most of PNPs (3), can cause unwanted side 
effects. Higher doses need to be applied to counteract 
premature drug release and to achieve therapeutic 
drug concentration at the target site. Drug release 
from PNPs has already been investigated in numerous 
studies, but the results obtained for a specific PNP 
formulation cannot be generalized to all PNPs (9). 
Since PLGA degrades in aqueous medium, colloidal 
stability of PNP dispersions is often a problem (15). 
To circumvent this hurdle, PNPs are usually freeze-
dried in order to achieve better physico-chemical 
stability of the formulation. Moreover, hydrolysis of 
PLGA in aqueous medium can also impact stability of 
the drug incorporated. Because of the acidic nature of 
PLGA degradation products, PNPs are not suitable 
for delivery of acidolabile drugs (9). 
When talking about TDD with PNPs there are also 
two disadvantages, which need to be considered. 
First, the EPR effect can vary from model to model 
used, more specifically also from patient to patient, 
and therefore its effect in vivo could be limited. 
Second, the potential efficacy of the active targeting 
is often overestimated (9). 
Figure 6. Disadvantages of PNPs. 
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Up to now, in vivo toxicity studies have revealed encouraging results i.e. low toxicity 
potential of PNPs. However, in vivo behaviour and pharmacokinetics of PNPs are still not 
completely understood, due to complexity of interactions between PNPs and biological 
systems (3, 8). 
There are also some limitations related to the preparation of PNPs, such as lack of 
reproducibility, additional purification steps needed after PNPs preparation, limited 
knowledge about the impact of numerous process parameters on final formulation, difficult 
scale-up, and high costs of GMP (good manufacturing practice) production (8, 9). 
All of the drawbacks, which are summarized in Figure 6, should be addressed in the near 
future to enable faster transition of PNPs from research into clinical studies.  
1.6. PNPs in current disease management 
Since drawbacks associated with PNPs limit the transition of PNP based formulations into 
clinical practice, it is not surprising that most of them are (still) in the preclinical (or in 
vitro) studies (3). Although more than twenty nanoparticle-based therapeutics have been 
approved for clinical use, none of them is based on PNPs. Furthermore, only a few 
nanoparticle-based therapeutics are currently in clinical trials (15), again without PNP 
formulations (8). However, there are many formulations currently in research or 
development for different diseases. 
One of the most interesting applications of PNPs is cancer treatment. PNPs may deliver 
both hydrophobic and hydrophilic anticancer drugs to the tumours, either passively or 
actively. Through such targeted delivery lower doses of anticancer drugs are needed, which 
reduces side effects and multidrug resistance of cancer cells (13). The studies have 
reported co-encapsulation of multiple drugs, which are commonly used in co-therapy of 
the cancer, in PNPs (e.g. docetaxel, doxorubicin and cyclophosphamide; paclitaxel and 
cisplatin, paclitaxel and erlotinib, paclitaxel and verapamil, paclitaxel and epigallocatechin 
gallate) (8). As nanotheranostics, PNPs are carriers for magnetic nanoparticles, which 
enable magnetic resonance imaging (7, 9), and chemotherapeutic drugs. They can be used 
for magnetic hyperthermia, as well as in photodynamic or photothermal therapy (8).  
PNPs can be used also in the treatment of (i) neurodegenerative diseases (e.g., Alzheimer 
disease, Parkinson disease, multiple sclerosis), (ii) inflammatory disorders (e.g., 
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inflammatory bowel disease, atherosclerosis, ulcerative colitis), (iii) cardiovascular 
diseases (e.g., controlled imaging and drug delivery for restenosis, atherosclerosis, 
myocardial infarction), (iv) infections, (v) treatment of cerebral diseases (e.g. passive 
delivery of proteins across blood brain barrier), (vi) osteoporosis, (vii) diabetes and in the 
future probably (viii) nerve regeneration and also for delivery of (ix) vaccines (3, 7). 
A lot of research is still needed in order to translate PNPs from research into clinical 
practice, however the above mentioned examples raise hope that the progress will open up 
new treatment options with PNPs in the near future. 
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2. Objectives 
A lot of work still has to be done to bring PNP formulations to clinical practice as 
discussed in the introduction. Thus, we assume that future investigations should be focused 
on the development of preparation and characterization protocols that will enable precise 
control of nanoparticle characteristics and their reproducible preparation. 
Therefore, the main aim of the present study is development of optimized protocols for the 
preparation of non-functionalized and functionalized PNPs with well-defined 
characteristics. Based on a literature review we will select an appropriate method for PNP 
preparation, which will be further optimized with respect to the properties of obtained PNP 
dispersions. For the preparation of functionalized (coated) PNPs chitosan and PEI will be 
used. (Non-)functionalized PNPs will be precisely characterized regarding hydrodynamic 
particle size, particle size distribution, zeta potential, surface morphology and solid state 
characteristics. Additionally, a method based on adsorption of Rose Bengal dye will be 
developed for evaluation of surface hydrophilicity/hydrophobicity of PNPs and rheology 
studies will be carried out to identify interactions between coating polymers and 
nanoparticle surface. PNP dispersions prepared according to the optimized protocols will 
be freeze-dried and stability of freeze-dried products will be investigated over a time 
period of 2 months. Finally, the interactions of selected PNP formulations with cells will 
be studied in vitro using human buccal TR 146 cells. The work plan is presented in Figure 
7. 
Figure 7. Laboratory work flow chart. 
17 
 
3. Materials and Methods 
3.1. Materials 
All chemicals used in our laboratory were of reagent grade from commercial suppliers. 
Poly(vinyl alcohol) (PVA), low molecular weight chitosan (50-190 kDa; chitosan), Rose 
Bengal sodium salt (C20H2Cl4I4Na2O5; RB), polyethylenimine, branched (25 kDa; PEI) 
and 1,1′ - dioctadecyl - 3,3,3′,3′ - tetramethylindocarbocyanine perchlorate (DiI) were 
purchased from Sigma-Aldrich GmbH (Steinheim, Germany). Poly(lactic-co-glycolic) acid 
(Resomer
®
 RG 503) was purchased from Evonik Industries AG (Essen, Germany). Ethyl 
acetate was obtained from Carl Roth GmbH (Karlsruhe, Germany). Acetic acid (glacial) 
100% and 1 M sodium hydroxide solution were purchased from Merck KGaA (Darmstadt, 
Germany).  
Ultrapure water (termed “water” in the following chapters) used in our study was prepared 
at the University of Graz, Institute of Pharmaceutical Sciences, Department of 
Pharmaceutical Technology & Biopharmacy, using a Milli-Q
®
 Gradient purifier (Millipore 
GmbH, Vienna, Austria). Ultrapure water used for the measurements of zeta potentials was 
adjusted with 0.9% (w/v) sodium chloride to a conductivity of 50 μS/cm and pH between 
5.5 and 6.0. 
For cell studies all media and stains used were from Gibco® Thermo Fischer Scientific 
Inc. (Waltham, Massachusetts, USA), including Dulbecco's Modified Eagle Medium 
(DMEM), Non-Essential Amino Acid (NEAA) cell culture supplement, penicillin-
streptomycin solution with 10,000 units ea. (PEST), fetal bovine serum (FBS) and 
phosphate buffered saline (PBS; pH 7.4, ionic strength of 162.7 mM) and Alexa Fluor 488 
Phalloidin and Hoechst 33342. Other chemicals for cell studies were purchased from 
Sigma-Aldrich GmbH (Steinheim, Germany), including: 0.1% Triton™ X-100, bovine 
serum albumin (BSA) and 10% formalin solution (neutral-buffered).  
3.1.1. PLGA characteristics 
The characteristics of the PLGA polymer (Resomer
®
 RG 503H) used in this study were 
provided by the producer (21). PLGA was composed of lactide and glycolide monomers in 
molar ratio 50:50. Its molecular weight was between 24,000-38,000 Da. Its intrinsic 
viscosity was described as 0.32-0.44 dL/g (for 0.1% (w/v) solution of polymer in 
chloroform at 25 °C) and its glass transition temperature was between 44-48 °C, while 
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degradation time frame was stated to be less than 3 months. The surface hydrophobicity of 
the polymer powder used was determined additionally as described in chapter 3.4.2.. 
3.2. Preparation of PNPs 
For preparation of PNPs, we used emulsion-diffusion-evaporation method. The basic 
preparation method was adopted from N. Nafee et al. (22). 
For preparation of all PNP formulations (coated and uncoated) water phase was firstly 
prepared as follows. The stabilizer (i.e., 125 mg of PVA) was dissolved in 5 mL of water at 
50 °C under moderate magnetic stirring, in a beaker covered with parafilm. During the 
cooling of the water phase to room temperature (25 °C), the organic phase was prepared. 
For this purpose, 100 mg of PLGA was dissolved in 5 mL of ethyl acetate by gentle hand 
shaking of the beaker, which was covered with parafilm. Both phases (water and organic 
phase) were combined using an automatic dispenser (EDOS 5222 Electronic Dispensing 
System; Eppendorf AG, Hamburg, Germany). 20 μL drops of the organic phase produced 
by the automatic dispenser were added to the water phase every 7 s, while stirring the 
sample on magnetic stirrer at room temperature (25 °C). The obtained o/w emulsion was 
further homogenized with a rotor-stator (high-speed) homogenizer (T25 digital Ultra 
Turrax
®
; IKA-Werke GmbH, Staufen, Germany) at 17,000 rpm for 10 min in a cold water 
bath to prevent heating of the sample. Then, 40 mL of water was added dropwise to 
homogenized emulsion using an automatic dispenser (200 μL drops, every 7 s, stirring on 
magnetic stirrer, 25 °C). The final dispersion was stirred on magnetic stirrer overnight (20-
24 h) at room temperature (25 °C), covered with a perforated parafilm to assure 
evaporation of ethyl acetate. After 24 h, the sample was transferred into a 50 mL falcon 
tube, where the pH value was measured (pH-meter Lab860; SCHOTT-Instruments GmbH, 
Mainz, Germany) and the dispersion was stored in the fridge at 2-8 °C. In order to prepare 
nanoparticles with desired characteristics, we have investigated more closely the influence 
of selected preparation parameters on the characteristics of PNPs. 
3.2.1. Preparation of uncoated PNPs 
To optimize the basic protocol for the preparation of uncoated PNPs, we firstly 
investigated the influence of different stirring rates during the preparation process on the 
average particle size, PDI and zeta potential of PNPs. Different stirring rates, i.e. 150 rpm, 
19 
 
300 rpm and 450 rpm, were investigated in all preparation steps. Samples were prepared in 
triplicates. 
Secondly, we investigated the influence of stabilizer concentration on the particle size, thus 
we have prepared PNPs with higher amounts of stabilizer (PVA) compared to the basic 
protocol.  
Finally, we have changed the container where homogenization was performed. Thus the 
homogenization step was carried out in a 50 mL narrow glass container (instead of a 
beaker), with the aim to achieve more efficient homogenization, which would result in 
smaller particle size and narrow particle size distributions of PNPs. 
The final optimized protocol (with exact amounts of substances used) for the preparation 
of uncoated PNPs is shown in Figure 8. 
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Figure 8. Preparation protocol for uncoated PNPs. 
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3.2.2. Preparation of chitosan-coated PNPs 
Chitosan-coated PNPs were produced according to the slightly modified protocol, which 
was used for the preparation of uncoated PNPs. All steps were practically the same, except 
the initial preparation of the water phase. More precisely, after dissolution of PVA in water 
(at 50 °C and moderate magnetic stirring), the water phase was removed from the heater 
and the pH was adjusted using three drops of glacial acetic acid, then chitosan was added. 
The water phase, containing dissolved PVA and chitosan, was cooled down to room 
temperature (25 °C) and used for further preparation of PNPs as described in chapter 3.2..  
We have investigated the impact of chitosan concentration in water phase on particle size 
and zeta potential of PNPs. Thus 10 mg, 12.5 mg, 25 mg or 50 mg of chitosan was 
dissolved in water phase and obtained PNP samples were characterized regarding the 
average hydrodynamic particle size, PDI and zeta potential.  
Due to the addition of glacial acetic acid the prepared PNP dispersions were acidic and 
showed poor physical stability. Therefore, immediate after preparation of PNPs the pH of 
the samples was adjusted to 5.50 with 0.1 M sodium hydroxide solution. 
The final optimized protocol (with exact amounts of substances used) for preparation of 
chitosan-coated PNPs is shown in Figure 9.  
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Figure 9. Preparation protocol for chitosan-coated PNPs. 
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3.2.3. Preparation of PEI-coated PNPs 
For PEI-coated PNPs, the preparation procedure was similar to the one used for 
preparation of the chitosan-coated PNPs. However, PEI was dissolved without addition of 
glacial acetic acid to the water phase. We investigated the impact of PEI concentration on 
the coating of PNPs. Thus different amounts of PEI, i.e., 12.5 mg, 25 mg, 50 mg, 200 mg 
or 400 mg were dissolved in water phase. The obtained PNP samples were characterized 
regarding the average hydrodynamic particle size, PDI and zeta potential.  
The final protocol (with exact amounts of substances used) for preparation of PEI-coated 
PNPs is shown in Figure 10. 
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Figure 10. Preparation protocol for PEI-coated PNPs. 
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3.2.4. Reproducibility of PNP preparation 
The reproducibility of the methods used for preparation of PNPs remains challenging. 
Therefore, we investigated the reproducibility of the preparation of PNPs by our optimized 
protocols. The similarity of samples was determined based on comparison of all basic 
parameters of PNPs. Preparation of all PNP samples (i.e, uncoated, chitosan-coated and 
PEI-coated PNPs) was performed twice and the characteristics of PNP dispersions 
(average hydrodynamic particle sizes, PDI, zeta potentials and pH values) were compared.  
3.3. Freeze-drying of PNP dispersions 
To improve long term physical and chemical stability prepared PNP dispersions were 
freeze-dried and the weight concentrations of PNP dispersions were determined based on 
dry weight of the products. 
Briefly, empty 10 mL vials were weighted and then filled with 3 mL of homogenous PNP 
dispersion. Samples were frozen using an ultra-low temperature freezer (Arctiko Uluf 65
®
; 
Arctiko A/S, Esbjerg, Denmark) at -80 °C for 3 h. Next, frozen samples were put in the 
freeze-dryer (Lyovac GT 2; SRK Systemtechnik GmbH, Riedstadt, Germany) with a 
starting pressure of 2 mbar and were left there for 48 h to reach the endpoint pressure of 
0.06 mbar. Immediately after freeze-drying, the vials were closed with gum closures and 
aluminium caps. The vials, containing the freeze-dried products were weighted again to 
determine the mass of PNPs and calculate the mass concentrations of the initial PNP 
dispersions. Freeze-dried samples were stored in closed vials in the fridge (2-8 °C).  
Stability of freeze-dried samples was investigated at predetermined time points (i.e., 
immediately after freeze-drying, and after one and two months). Samples were re-
dispersed in 3 mL of water using a vortex stirrer for approximately 5 min. Hydrodynamic 
particle size, PDI and zeta potential of PNPs were measured as described in the chapter 
3.4.1.. 
3.4. Characterization of PNPs 
3.4.1. Hydrodynamic particle size and zeta potential  
The mean hydrodynamic particle size of the PNP dispersions and re-dispersed freeze-dried 
products was determined by photon correlation spectroscopy (PCS, ZetaSizer Nano ZS; 
Malvern Instruments, Malvern, United Kingdom). Measurements were carried out at room 
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temperature (25 °C) with 30 s equilibration time in water (20 μL of PNP sample was 
diluted with 980 μL of water to assure a suitable sample concentration). A cuvette 
(DTS0012 cell) was filled with the sample and measurement was conducted with a 532 nm 
laser at a measurement angle of 173 ° (backscatter). The final results are expressed as 
average hydrodynamic particle size (d [nm]) and width of particle size distribution (PDI) 
of three independent measurements (with standard deviations).  
Zeta potential was measured employing laser Doppler anemometry (scattering angle 173 °) 
coupled with PCS. The measurements were performed at room temperature (25 °C) in 
water with adjusted conductivity (20 μL of PNP sample was diluted with 980 μL of water 
with adjusted conductivity). The sample was filled in a cuvette (DTS1070 cell) and the 
measurement was performed. The final results are expressed as average zeta potential ( 
[mV]) of three independent measurements (with standard deviation). 
3.4.2. Surface hydrophobicity (Rose Bengal assay)  
In order to determine surface hydrophobicity of the prepared PNPs, a Rose Bengal assay 
was developed based on the methods previously described by S. Doktorovova et al. (23) 
and C. Tetyzcka (24). The procedure used in this study is presented in Figure 11. 
A stock water solution of Rose Bengal sodium salt (C20H2Cl4I4Na2O5) was prepared in a 
concentration of 1 mg/mL. It was used for preparation of Rose Bengal solutions with 
concentrations of 10, 20, 30 or 40 μg/mL, which were prepared at room temperature (25 
°C) protected from light. Next, mixtures of PNP dispersion and RB solutions were 
prepared as presented in Table I. Blank measurement was performed using 200 μL of the 
PNP sample and 800 μL of water. The standard solutions consisted of 1000 μL of RB 
solution (concentrations 10-40 μg/mL). All PNP samples (200 μL) were mixed and 
incubated with the RB solutions in three parallels (A, B, C). Additionally, the assay was 
performed also for 1000 μL of water. 
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Table I. Samples used in Rose Bengal assay. 
Measurement 
Water 
[μL] 
Tested 
sample [μL] 
RB 10 
μg/mL [μL] 
RB 20 
μg/mL [μL] 
RB 30 
μg/mL [μL] 
RB 40 
μg/mL [μL] 
Blank 800 200 0 0 0 0 
MQ 1000 0 0 0 0 0 
Standard 1 0 0 1000 0 0 0 
Standard 2 0 0 0 1000 0 0 
Standard 3 0 0 0 0 1000 0 
Standard 4 0 0 0 0 0 1000 
1A/1B/1C 0 200 800 0 0 0 
2A/2B/2C 0 200 0 800 0 0 
3A/3B/3C 0 200 0 0 800 0 
4A/4B/4C 0 200 0 0 0 800 
All samples were incubated covered with aluminium foil for 3 h at 25 °C in a thermoblock 
(IKA Dry Block Heater 2; IKA-WerkeGmbH, Staufen, Germany). Immediately after 
incubation, 200 μL of each solution was withdrawn (in three parallels) and transferred into 
a 96 well plate (Cellstar
®
; Greiner Bio-One GmbH, Friedrichshafen, Germany). UV/VIS 
absorption was measured using a UV/VIS spectrophotometer (FluoSTAR
®
 Galaxy; BMG 
Labtech GmbH, Offenburg, Germany), with an excitation filter at 544 nm, no emission 
filter and gain adjusted to 59 to determine the amount of unbound RB. Furthermore, for 
calculation of correction factor, which was necessary to correct possible shifts in the 
Figure 11. Protocol for modified Rose Bengal assay. 
28 
 
absorption maxima (see below), 200 μL of each sample was used to record UV/VIS 
spectra from 200 to 700 nm (NanoPhotometer
®
 P 300; Implen GmbH, Munich, Germany). 
A calibration curve was constructed based on measurements of the standard solutions; 
which were also used as controls during the development of the assay to reveal any 
adsorption of RB on the plastic tubes. The concentration of free RB (RBfree) [μg/mL] was 
calculated based on the measured absorbance (subtracted by the blank sample absorbance) 
and a calibration curve was created using equation 1.  
𝐴𝑐𝑜𝑟𝑟. = 𝑘𝑐 + 𝑛 
Equation 1. Calibration curve for calculation of free RB.  
where Acorr. is the corrected UV/VIS absorption of (free) RB (according to equation 2), k is 
the slope of calibration curve [mL/μg] and n is the intercept of the calibration curve. 
The correction factor was calculated for samples, where a red shift of absorption maximum 
of RB was present. It was presumed that the red shift caused a change of the absorption 
maxiumum towards higher wavelengths, not influencing the intensity of the absorption. 
The proportion between the sample absorption at λmax of the sample (Amax
sample
) and the 
sample absorption at the λmax of RB (measured for standard solutions ARBmax
sample
) was 
calculated from recorded spectra using the NanoPhotometer
®
 and applied as correction 
factor (CF). The product of measured A544 and CF was Acorr. (as shown in equation 2) and 
was used for further calculations. The value of the CF was taken as 1 in case that the red 
shift of the absorption maximum was not present.  
𝐴𝑐𝑜𝑟𝑟. =  𝐴544 ∙
𝐴𝑚𝑎𝑥
𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑅𝐵𝑚𝑎𝑥
𝑠𝑎𝑚𝑝𝑙𝑒 = 𝐴544 ∙ 𝐶𝐹  
Equation 2. Calculation of corrected value of free RB. 
The concentration of adsorbed RB was calculated using equation 3.  
[𝑅𝐵𝑏𝑜𝑢𝑛𝑑] =  [𝑅𝐵𝑎𝑑𝑑𝑒𝑑] −  [𝑅𝐵𝑓𝑟𝑒𝑒] 
Equation 3. Calculation of adsorbed RB. 
where [RBbound] is the concentration of adsorbed RB, [RBfree] is the concentration of free 
RB and [RBadded] the initial concentration of RB (all three in μg/mL). 
For the construction of the Scatchard plot, the ratio [RBbound]/[RBfree] was calculated and 
the Scatchard plot lines for [RBbound]/[RBfree] = f ([RBbound]) were constructed using 
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Microsoft Excel 2010, considering three out of four points with the best correlation. The 
equation for the line in Scatchard plot is shown by equation 4: 
𝑅𝐵𝑏𝑜𝑢𝑛𝑑
𝑅𝐵𝑓𝑟𝑒𝑒
=  −𝐾 ∙ 𝑅𝐵𝑏𝑜𝑢𝑛𝑑 + 𝐾 ∙ 𝑁 
Equation 4. Scatchard plot line. 
The results are expressed as theoretical parameters, i.e., intercept “N” (maximal adsorbed 
amount of RB) of the Scatchard plot [μg/mL] and slope “K” (adsorption constant) of the 
Scatchard plot [mL/μg]. Additionally, the maximal adsorbed amount of RB on the 
nanoparticles in μg/mg (i.e., Rose Bengal adsorption - RBA) was calculated as a quotient 
of theoretical parameter N and mass concentration of the PNP sample, which represented 
the final result of Rose Bengal assay. 
The established assay was carried out with all three formulations of PNPs, i.e., uncoated 
PNPs, chitosan-coated PNPs and PEI-coated PNPs. Moreover, pure dispersions of 
polymers, namely PLGA, chitosan and PEI, were also studied. For this purpose, 50 mg of 
PLGA powder was suspended in 20 mL (0.25% (w/v) suspension) water using a rotor-
stator homogenizer (T25 digital Ultra Turrax®; IKA-WerkeGmbH, Staufen, Germany) at 
17,000 rpm for 10 min. 6.3 mg of chitosan was dissolved in 20 mL water with addition of 
three drops of glacial acetic acid at room temperature (25 °C) to obtain a 0.03% (w/v) 
solution. 6.3 mg of PEI was dissolved in 20 mL water at ~50 °C under moderate magnetic 
stirring, to obtain a 0.03% (w/v) solution. 
3.4.3. Rheology studies 
Rheology measurements were carried out to investigate whether chitosan or PEI interact 
with the particle surface. Additional to PNP dispersions also chitosan and PEI solutions in 
the same concentration as that used for nanoparticle preparation (i.e., 0.03% (w/v)) were 
investigated. 
The chitosan solution was prepared by dissolving 6.3 mg of chitosan in 20 mL water 
(0.03% (w/v) solution) with addition of 3 drops of glacial acetic acid at 25 °C under 
moderate stirring on a magnetic stirrer. The PEI solution was prepared by dissolving 6.3 
mg of PEI in 20 mL of water (0.03% (w/v) solution) under moderate stirring on a magnetic 
stirrer at 50 °C and subsequent cooling to 25 °C. 
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Rheology measurements were carried out in triplicates using a rheometer (Physica MCR 
301; Anton Paar, Graz, Austria) with an oscillatory measurement system CP50. 700 μL of 
the sample was placed on the plate of rheometer and measurements were carried out at 
angular frequencies from 0.1 to 10.0 rad/s (25 °C). The average (kinematic) viscosity (η 
[Pas]) and the storage modulus (G’ [Pa]; which describes the elastic portion, also defined 
as quasi solid state behaviour of the system (25)) were determined depending on the 
angular frequency. 
3.4.4. Scanning electron microscopy imaging 
The morphology of the prepared PNPs was examined by field emission scanning electron 
microscopy (SEM; Supra 35 VP; Carl Zeiss, Oberkochen, Germany) operated at 
acceleration voltage of 8 kV with a secondary detector.  
The sample purification prior to SEM imaging was performed by centrifugation. 1 mL 
sample of PNPs was centrifuged (14,000 rpm (20817 g), 5 °C, 10 min) using ultra 
centrifuge (Eppendorf Centrifuge 5804 R; Eppendorf AG, Hamburg, Germany). The 
supernatant was withdrawn, the sediment was re-dispersed in 1 mL of water, and was 
centrifuged (14,000 rpm, 5 °C, 10 min) again. The washing step was carried out twice. 
Prior to SEM imaging, 3 µL drops of PNP dispersions were placed on standard pin studs 
and dried at room temperature (25 °C). In case of freeze-dried samples a small amount of 
sample was fixed with double-sided conductive tape on standard pin studs. Both purified 
and freeze-dried samples of PNPs were then coated with a 5 nm gold layer. 
3.4.5. Differential scanning calorimetry 
The thermal characteristics of the prepared (un)coated PNPs after freeze-drying were 
studied by differential scanning calorimetry (DSC). The results were compared with the 
DSC curves of pure PLGA (powder), PVA (powdered pellets), chitosan (powder), PEI 
(viscous liquid) and the physical mixtures of polymers. 
For this purpose, PVA pellets were grinded into a powder using a grinding mill (Ultra 
centrifugal Mill ZM 100; Retsch GmbH, Haan, Germany). The powdered PVA was used 
for both, the pure PVA and the physical mixture measurements. Physical mixtures of 
polymers equivalent to the composition of PNP formulations were prepared in weight 
ratios shown in Table II, using mortar and pestle for homogenization of the mixture.  
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Table II. Physical mixtures of polymers used for DSC measurements. 
Polymers Weight ratio  Equivalent PNP sample 
PLGA:PVA 4:5 uncoated PNPs 
PLGA:PVA:chitosan 8:10:1 chitosan-coated PNPs 
PLGA:PVA:PEI 8:10:1 PEI-coated PNPs 
Samples (1.5–15.0 mg, depending on the sample nature) were precisely weighted and 
sealed in aluminium pans with pierce in lid and placed in the apparatus (DSC 204 F1 
Phoenix®; Erich NETZSCH GmbH & Co. Holding KG, Selb, Germany). Empty 
aluminium pan with pierce in lid served as reference. The temperature program used is 
presented in Figure 12. 
The DSC cell was purged with pure nitrogen (flow rate 20 mL/min). Data were analysed 
with Proteus Thermal Analysis software (Erich NETZSCH GmbH & Co. Holding KG) and 
average temperature of peaks were calculated based on two measurements. 
3.4.6. Cell interaction studies 
In order to study cellular interactions, PNPs were loaded with fluorescent dye 1,1′ - 
dioctadecyl - 3,3,3′,3′ - tetramethylindocarbocyanine perchlorate (DiI), which enabled 
particle tracking. The procedure of PNP preparation was as described in chapter 3.2. with 
slight modifications, i.e. 9.35 mg of DiI was dissolved in ethyl acetate together with PLGA 
and the stained samples were treated (and stored) in the dark.  
Figure 12. Temperature program used in DSC analysis. 
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To examine, whether DiI was efficiently entrapped in PNPs, fluorescence spectrometry 
(FluoSTAR® Galaxy; BMG Labtech GmbH, Offenburg, Germany) was employed. First, 
500 μL of each PNP sample was transferred into micro centrifuge tube equipped with 
centrifugal filters (Amicon®Ultra centrifugal filters; Merck Millipore Ltd, Tullagreen-
Carrigtwohill, Ireland) and centrifuged at 14,000 rpm (5 °C; 10 min) using an ultra-
centrifuge (Eppendorf Centrifuge 5804 R; Eppendorf AG, Hamburg, Germany). Next, the 
filtrates were incubated in an ultrasound bath for 10 s and vortexed for 15 s to achieve 
complete dissolution of DiI if present in the filtrate. 200 μL of the filtrate (in duplicates) or 
PNP sample (in triplicates) was transferred into a 96 well plate (Lumitrac
®
 200; Grenier 
Bio-One GmbH, Friedrichshafen, Germany) and the fluorescence intensity was measured 
(excitation filter at 544 nm, emission filter at 599 nm and gain adjusted to 110). The 
entrapment efficiency of DiI (expressed as percentage of DiI used in nanoparticle 
preparation) was calculated using equation 5. 
𝑑𝑦𝑒 𝑒𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 [%] =  
𝐼𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐼𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑒
𝐼𝑠𝑎𝑚𝑝𝑙𝑒
 ∙ 100% 
Equation 5. Calculation of the dye entrapment efficiency. 
where Isample and Ifiltrate are the fluorescence intensities of the dye in PNP sample and 
filtrate, respectively.  
Cellular interaction studies were carried out on human buccal TR 146 epithelial cells 
provided by Imperial Cancer Research Technology; London, UK. The cells (150,000 per 
well) were seeded in a glass-bottom 24 well plate (Cellstar®; Greiner Bio-One GmbH, 
Friedrichshafen, Germany) and were cultivated in cell culture medium (10% FBS, 1% 
PEST and 1% NEAA in DMEM), which was changed every second day, until the cell 
confluency was reached, then the experiment was performed (on the 6
th
 day). 
PNP samples were firstly diluted with serum-free medium (i.e., DMEM without phenol 
red) to approximate concentration (100 μg/mL or 200 μg/mL). Cells were washed with 250 
µL of pre-warmed PBS (pH 7.4; 37 °C) and subsequently incubated with 500 μL of the 
diluted PNP sample (in duplicates) for 4 h at 37 °C. Control cells were incubated with 
serum-free medium only (in duplicates) under the same conditions. After incubation, cells 
were washed twice with 250 µL PBS and fixed with 10% formaldehyde solution (250 μL) 
for 10 min at room temperature (25 °C). Next, the cells were washed twice with 250 µL 
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PBS and then 0.1% solution of Triton™ X-100 in water (250 μL) was added. After 5 min, 
cells were washed twice with 250 µL PBS and the staining solution (200 μL) was added 
for 30 min at room temperature (25 °C). The staining solution was prepared right before 
cell staining from 3 mL PBS (with 1% BSA), 75 μL Alexa Fluor 488 Phalloidin and 7.5 
μL Hoechst 33342. Finally, the stained cells were washed twice with 250 µL PBS, then 
fresh 250 µL of PBS was added and cells were stored in the fridge until imaging was 
performed.  
A confocal laser scanning microscope (LSM510 Meta; Carl Zeiss, Oberkochen, Germany) 
with 405 nm/bandpass 420-480 nm laser for the blue channel (nuclei), 543 nm/longpass 
560 nm laser for the red channel (PNPs) and 488 nm/bandpass 505-550 nm laser for the 
green channel (cytoskeleton) was used. 
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4. Results 
4.1. Preparation of uncoated PNPs 
The initial method for preparation of uncoated PNPs was adopted from N. Nafee et al. (22) 
and further modified for the preparation of coated PNPs. 
To investigate the influence of stirring rate during the preparation procedure of uncoated 
PNPs (during formation of o/w emulsion, dilution of emulsion with water and evaporation 
of organic solvent) on the particle size, particle size distribution, and zeta potential of 
PNPs, studies were performed at three different stirring rates, i.e. low (150 rpm), moderate 
(300 rpm) and high (450 rpm). It was shown that the use of higher stirring rates led to 
smaller PNP sizes (Figure 13A). However, no effect was observed either on the PDI or on 
the zeta potential of PNPs (Figure 13B and C). 
A 
B 
C 
Figure 13. Average hydrodynamic particle size (A), PDI (B) and zeta potential (C) of 
uncoated PNPs prepared at different stirring rates (150 rpm, 300 rpm and 450 rpm). 
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In addition to the stirring rate, the influence of stabilizer concentration in water phase on 
properties of PNPs was investigated. A higher amount of PVA in the aqueous phase (i.e., 
150 mg) resulted in a smaller size of PNPs (Figure 14A), while the PDI as well as the zeta 
potential values did not change (Figure 14B and C). 
The formulation (here referred as formulation X) with the smallest particle size and low 
PDI was obtained at the stirring rate of 450 rpm and the addition of 125 mg of PVA into 
the water phase. Moreover, during homogenization a narrow glass container was used 
instead of a beaker. The average hydrodynamic size of PNPs was 231.0 ± 1.3 nm, PDI was 
0.078 ± 0.020 and the zeta potential was -5.19 ± 0.57 mV. The formulation X was used in 
further studies. 
4.2. Preparation of chitosan-coated PNPs 
The preparation of chitosan-coated PNPs was based on the protocol used for preparation of 
formulation X. In order to achieve the most optimal coating, we prepared PNP samples 
using different amounts of chitosan in the water phase, i.e. 10 mg, 12.5 mg, 25 mg or 50 
mg (Figure 15).  
A 
B 
C 
Figure 14. Average hydrodynamic particle size (A), PDI (B) and zeta potential (C) of 
uncoated PNPs prepared with different amounts of stabilizer (PVA). 
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The results revealed that the average hydrodynamic size of PNPs increased with increasing 
amount of chitosan in water phase. Similar trend was observed for the PDI and the zeta 
potential of PNP dispersions. No further changes in PDI and zeta potential were observed 
after addition of more than ~30 mg of chitosan. Thus, the final formulation of the chitosan-
coated PNPs (here referred to as formulation CX) contained 12.5 mg chitosan (core 
polymer to coating weight ratio was 8:1). The theoretical thickness of nanoparticle coating 
in dispersion was ~95 nm, particles showed a positive zeta potential (+31.47 ± 0.49 mV) 
and the PDI of 0.241 ± 0.008. 
4.3. Preparation of PEI-coated PNPs 
PEI-coated PNPs were prepared with 12.5 mg, 25 mg, 50 mg, 200 mg or 400 mg PEI in the 
water phase (Figure 16). 
Figure 15. Average hydrodynamic particle size (A), PDI (B) and zeta potential 
(C) of PNPs depending on the amount of chitosan in the water phase. 
C 
B 
A 
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Compared to formulation CX, PEI-coated PNPs showed a decrease in particle size with 
increasing amount of PEI in dispersion. The PDI values and zeta potential of PNP 
dispersions were not affected by the amount of PEI used. 
Based on these results, the final formulation of PEI-coated PNPs (here referred to as 
formulation PX) was prepared with 12.5 mg PEI (core polymer to coating weight ratio 
was 8:1). The theoretical thickness of nanoparticle coating in dispersion was ~35 nm, 
particles showed a positive zeta potential (+11.77 ± 0.64 mV) the PDI of 0.143 ± 0.017. 
4.4. Reproducibility of PNP preparation 
In order to investigate the reproducibility of PNP preparation, formulations X, CX and PX 
were prepared twice according to the optimized protocols. The results are presented in 
Figure 17. 
A 
B 
C 
Figure 16. Average hydrodynamic particle size (A), PDI (B) and zeta 
potential (C) of PNPs depending on the PEI amount in the water phase. 
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The results show that the preparation of uncoated and PEI-coated PNPs is well 
reproducible. However, preparation of chitosan-coated PNPs showed some variations in 
particle size, PDI and zeta potential. 
4.5. Freeze-drying of PNP dispersions 
Based on the mass of the freeze-dried PNP dispersions the final weight concentrations of 
X, CX and PX dispersions were calculated. It was shown that the concentration of all 
dispersions was in the same concentration range, i.e., 6.11 ± 0.01 mg/mL, 5.27 ± 0.05 
mg/mL and 6.00 ± 0.05 mg/mL for formulations X, CX and PX, respectively. 
All freeze-dried products were coloured white with appearance similar to cotton wool. The 
characteristics of re-dispersed freeze-dried samples were compared to the characteristics of 
initial PNP dispersions with regard to the average hydrodynamic particle size (Figure 
18A), the PDI (Figure 18B) and the zeta potential (Figure 18C). Freeze-dried formulation 
X (here referred as X-FD) and formulation PX (here referred as PX-FD) exhibited 
practically the same values of measured parameters as their initial PNP dispersions 
A 
B 
C D 
Figure 17. Average hydrodynamic particle size (A), PDI (B), zeta potential (C) and pH (D) of PNP 
dispersions for two repetitions of formulations X, CX and PX preparation. 
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(formulations X and PX, respectively). On the other hand, an increase in all investigated 
parameters was seen in case of re-dispersed freeze-dried formulation CX (here referred as 
CX-FD), which showed poor re-dispersibility after freeze-drying. 
Stability studies revealed that freeze-dried samples were stable for two months at 
temperature 2-8 °C, regarding average hydrodynamic particle size, PDI and zeta potential 
after re-dispersion of freeze-dried formulations (Figure 19). Although formulation CX-FD 
could not be re-dispersed properly, it exhibited stable values regarding the hydrodynamic 
particle size, PDI and zeta potential after re-dispersion. 
 
 
 
 
A 
C B
B 
Figure 18. Average hydrodynamic particle size (A), PDI (B) and zeta potential (C) for PNP formulations 
before (X, CX, PX) and after freeze-drying and re-dispersion (X-FD, CX-FD, PX-FD). 
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4.6. Characterization of final PNP formulations 
4.6.1. Hydrodynamic particle size and zeta potential  
The hydrodynamic particle size, PDI and zeta potential values of all formulations prepared 
during development of the final protocols for preparation of uncoated and coated PNPs are 
presented in chapters 4.1., 4.2., 4.3., 4.4. and 4.5.. Thus, this chapter presents only the 
parameters for the final formulations X, CX and PX (Table III). 
Comparing all three formulations, the smallest particle sizes were determined in case of 
uncoated PNPs, i.e. formulation X (231.0 ± 1.3 nm). Coating increased the hydrodynamic 
particle size for ~95 nm in case of chitosan and for ~35 nm in case of PEI (Table III). 
B 
A 
C 
Figure 19. Average hydrodynamic particle size (A), PDI (B) and zeta potential 
(C) of re-dispersed freeze-dried formulations X-FD, CX-FD and PX-FD. 
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Formulation X exhibited also lowest PDI value compared to PDI values of formulations 
CX and PX. Formulation X exhibited a slightly negative zeta potential (-5.19 ± 0.57 mV), 
while coating resulted in positive zeta potential of PNPs at pH from 5.0 to 5.5. To assure 
stability of the CX formulation, the pH of PNP dispersion was adjusted at the end of 
preparation procedure from approximately 4.0 to 5.5. 
Table III. Average hydrodynamic particle size (d), PDI, and zeta potential (ζ) of uncoated (formulation X), 
chitosan-coated (formulation CX) and PEI-coated (formulation PX) PNPs, as well as pH of PNP dispersions. 
Formulation X CX PX 
d [nm] 231.0 ± 1.3 325.1 ± 3.2 267.6 ± 1.8 
PDI 0.078 ±0.020 0.241 ± 0.008 0.143 ± 0.017 
 [mV] -5.19 ± 0.57 +31.47 ± 0.49 +11.77 ± 0.64 
pH 5.37 5.49 5.01 
The average hydrodynamic particle size distributions measured with the ZetaSizer are 
presented in Figure 20. Results show that formulation X had the narrowest particle size 
distribution (the lowest PDI in Table III), and formulation CX had the broadest particle 
size distribution (the highest PDI in Table III) among the studied formulations. 
4.6.2. Surface hydrophobicity (Rose Bengal assay) 
Surface hydrophobicity was determined by the modified Rose Bengal assay. pH values of 
RB solutions were adjusted to be about 6.0, which was in preliminary studies shown to be 
adequate for stability of PNP dispersions. In order to assure the accuracy and robustness of 
the developed assay, we considered different factors, which could influence the final 
results. As it is known that RB could aggregate on its own and might in some cases adsorb 
on plastic tubes (16, 23), standard solutions of RB were used as a control of RB 
aggregation and adsorption on the plastic tubes. No changes in the UV/VIS absorption 
spectra of RB were shown, suggesting that no aggregation of RB and no adsorption of RB 
Figure 20. Average hydrodynamic particle size distribution of uncoated (formulation X), chitosan-
coated (formulation CX) and PEI-coated (formulation PX) PNP samples. 
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on the plastic tubes were present. The wavelength of RB absorption maximum did not 
change for at least 24 h compared to RB absorption maximum right after the end of assay.  
Adsorption of RB on PNPs is expressed as the maximal amount of RB adsorbed on the 
PNPs (i.e. RBA) in μg/mg. The results were obtained based on the construction of a 
Scatchard plot (Figure 21). 
The final results (K, N and RBA values) of the surface hydrophobicity of investigated 
samples are presented in Table IV. 
Table IV. Results of the surface hydrophobicity of investigated samples. 
Sample K [mL/μg] N [μg/mL] RBA [μg/mg] 
PLGA powder 0.0329 17.93 35.18 
Formulation X 0.0228 48.82 44.55 
Formulation CX -0.0422 0.26 0.21 
Formulation PX 0.0813 32.43 29.00 
chitosan solution -0.0303 -28.25 -447.02 
PEI solution -0.0204 -40.68 -646.81 
Figure 21. Scatchard plot for the Rose Bengal assay for PLGA powder dispersion (PLGA) and 
PNP dispersions (formulations X, CX and PX). 
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A red shift of the absorption maximum of RB was observed in case of formulations CX 
and PX. The absorption maxima were shifted from 544 nm to (577 ± 1) nm and (558 ± 1) 
nm, for formulations CX and PX, respectively. For these samples a correction factor was 
calculated as described in chapter 3.4.2..  
The highest RBA value, representing the highest hydrophobicity of the sample, was 
obtained for formulation X (44.55 μg/mg), followed by the PLGA powder (35.18 μg/mg) 
and formulation PX (29.00 μg/mg). The lowest RBA value, representing the lowest 
hydrophobicity of the sample, was determined for formulation CX (0.21 μg/mg). This was 
confirmed by the Scatchard plot, where formulation CX was the only one having positive 
slope of Scatchartd plot line. When considering RBA values for chitosan and PEI solutions 
(Scatchard plot lines for them are not shown in Figure 21), the RBA values were negative, 
indicating that the modified Rose Bengal assay is not applicable for highly hydrophilic 
samples as reported previously by S. Doktorovova et al. (23). 
4.6.3. Rheology studies 
In order to compare PNP samples and to investigate the efficiency of the coating of PNPs, 
we carried out rheology measurements to study the (kinematic) viscosity (η) of PNP 
dispersions and determine the storage modulus (G’). The comparison of formulation CX 
with pure solution of chitosan (with the same concentration as in dispersion of PNPs) and 
formulation PX with pure solution of PEI (with the same concentration as in dispersion of 
PNPs) are demonstrated in Figure 22. All graphs (Figure 22 and 23) have logarithmic 
scales and thus should be carefully interpreted, when comparing the absolute differences 
between the measured values.  
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The results of formulation CX revealed that both, the kinematic viscosity and the storage 
modulus, were lower compared to the pure chitosan solution. Interestingly, only slight 
differences were observed between the PEI solution and formulation PX. The viscosity of 
all investigated samples decreased with increasing angular frequency, indicating shear 
thinning properties. 
The highest kinematic viscosity at the starting point (0.1 rad/s) of measurements was 
obtained for formulation X, whereas the lowest kinematic viscosity was determined for 
formulation PX (Figure 23). Viscosity curves for all three formulations of PNPs had 
similar shape. The storage modulus of formulation CX was measured at the lower angular 
frequencies (from 0.1 to 0.4 rad/s) compared to formulations X and PX, where a frequency 
of at least 0.4 rad/s was necessary to perform a measurement. Formulations X and PX 
exhibited similar elastic behaviour as indicated by the curve of storage moduli, especially 
at higher angular frequencies, where their storage moduli were similar. The storage 
modulus of formulation CX did not change with increase in angular frequency, showing 
that formulation CX had similar elastic behaviour at all angular frequencies. 
Figure 22. Correlation between kinematic viscosity (η) /storage modulus (G’) and the angular 
frequency (ω) for chitosan-coated (formulation CX) and PEI-coated (formulation PX) PNP dispersion 
compared to pure chitosan solution (0.03% (w/v)) and pure PEI solution (0.03% (w/v)) solution. 
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4.6.4. Scanning electron microscopy imaging 
SEM imaging of purified PNP dispersions (as described in chapter 3.4.4.) and freeze-dried 
PNP samples was firstly carried out without any coating. However, the samples turned out 
to be sensitive to the conditions used during imaging. They were getting smaller during 
imaging at higher magnifications until they completely disappeared. Therefore, we used 5 
nm gold layer coating to prevent PNPs from being damaged by electron beam as has been 
reported previously in other studies (26, 30, 31). 
Spherical to square-like morphologies of PNPs were observed in all samples. SEM images 
recorded at high magnification (Figure 24) revealed bridge-like connections between 
PNPs, which were more pronounced in formulations X and PX compared to formulation 
CX. Formulation CX formed a network, which enabled the PNPs to be uniformly arranged, 
while X and PX PNPs were more randomly arranged. The particle size of individual PNPs 
determined based on SEM images was slightly smaller (i.e., 150 nm to 300 nm) than the 
hydrodynamic particle size determined by PCS (Table III and Figure 25).  
Figure 23. Correlation between kinematic viscosity (η)/ storage modulus (G’) and angular 
frequency (ω) for uncoated (formulation X), chitosan-coated (formulation CX) and PEI-coated 
(formulation PX) PNP dispersion. 
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In Figure 26 for purified PEI-coated PNPs some porous structures, with diameter ranging 
from 300 nm to 400 nm, are seen, showing that that something besides PNPs was present 
in the sample. 
A 
B C 
Figure 25. SEM images of purified uncoated (formulation X; A), chitosan-coated (formulation CX; B) and 
PEI-coated (formulation PX; C) PNPs 
A 
B C 
Figure 24. SEM images of purified uncoated (formulation X; A), chitosan-coated (formulation CX; B) and 
PEI-coated (formulation PX; C) PNPs. 
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Compared to the purified PNP samples, freeze-dried formulations X-FD, CX-FD and PX-
FD showed a different morphology on SEM images (Figure 27). PNPs appeared hidden in 
a matrix. This phenomenon was the most obvious in case of formulation PX-FD, followed 
by formulation CX-FD and then formulation X-FD. 
4.6.5. Differential scanning calorimetry  
DSC measurements revealed that the freeze-dried PNPs mostly showed similar solid-state 
properties than pure PLGA powder, which had an endothermic peak at 53.2 ± 0.1 °C. No 
B C 
A 
Figure 27. SEM images of freeze-dried uncoated (formulation X-FD; A), chitosan-coated (formulation CX-
FD; B) and PEI-coated (formulation PX-FD; C) PNPs. 
Figure 26. SEM image of purified PEI-coated (formulation PX) 
PNPs. 
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peaks were observed on DSC curves of pure chitosan, PEI and PVA (Table V and Figure 
28). 
Table V. Peaks observed on DSC curves of pure polymers (PLGA, PVA, chitosan, PEI), physical mixtures 
with composition of uncoated (Xm), chitosan-coated (CXm) and PEI-coated (PXm) PNPs and for freeze-
dried formulations X-FD, CX-FD and PX-FD (the first heating cycle). 
Sample 
The first heating cycle up to 80 °C 
Peak [°C] 
PLGA 53.2 ± 0.1 
PVA ⁄ 
chitosan ⁄ 
PEI ⁄ 
Xm 47.0 ± 0.3 
CXm 47.1 ± 0.2 
PXm 46.3 ± 0.1 
X-FD 49.3 ± 0.1 
CX-FD 46.4 ± 0.0 
PX-FD 46.7 ± 0.3 
During the first heating cycle, the physical mixtures showed endothermic peaks in range 
from ~46 °C to ~47 °C. No shifts in the peak positions were observed for formulation CX-
FD and PX-FD compared to their physical mixtures. However, in case of formulation X-
FD the peak shifted towards higher temperatures compared to its physical mixture (Figure 
29). Freeze-dried PNPs showed endothermic peaks in the temperature range from ~46°C to 
~49°C. Formulation X-FD showed a peak at higher temperature than its physical mixture, 
but it was still lower than the peak temperature of pure PLGA (Table V). 
Figure 28. DSC curves of pure polymers (the first heating cycle). 
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4.6.6. Investigation of interactions between PNPs and TR 146 cells 
For cell interaction studies the fluorescent dye DiI was incorporated into the PNPs. 
Encapsulation efficiency of Dil was determined to be ~94% for all formulations, thus 
stained PNPs could be visualised by confocal laser scanning microscopy (CLSM). They 
were visible as red dots in CLSM images.  
Cell interaction studies were performed at two different concentrations of PNP dispersions, 
namely 100 and 200 μg/mL. However, no visible differences between these two 
concentrations were detected. CLSM imaging showed that PNPs in formulation X strongly 
interacted with the human buccal TR 146 epithelial cells. Uncoated PNPs were internalized 
to a greater extent than PNPs coated with chitosan or PEI (formulations CX or PX, 
respectively) (Figures 30 and 31). The positively charged PNPs in formulation CX strongly 
interacted with the outer cell membrane and were internalized to a minor extent, while the 
positively charged PNPs in formulation PX also interacted with the outer cell membrane 
but to a smaller extent compared to formulation CX and were not detected inside the cells. 
No red fluorescence was detected on CLSM images of control cells, indicating that no 
stained PNPs were present in control samples.  
 
 
Figure 29. DSC curves of physical mixtures (composition of uncoated (Xm), chitosan-coated (CXm) 
and PEI-coated (PXm) PNPs) and freeze-dried formulations X-FD, CX-FD and PX-FD (the first 
heating cycle). 
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Figure 30. CLSM images of TR 146 cells after being incubated with/without 
PNP dispersions for 4 h – serum-free medium (control; A), formulation X (B), 
formulation CX (C), formulation PX (D) (all PNP dispersions in concentration 
200 μg/mL);                                                                                                                                                                                          
nuclei were stained blue, cytoskeleton green and PNPs red. 
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Figure 31. CLSM images of TR 146 cells after being incubated with/without PNP dispersions for 4 h – 
serum-free medium (control; A), formulation X (B), formulation CX (C), formulation PX (D) (all PNP 
dispersions in concentration 100 μg/mL);                                                                                                                                                                                          
nuclei were stained blue, cytoskeleton green and PNPs red. 
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5. Discussion 
This study aimed to develop an optimized protocol for preparation of uncoated PNPs 
(formulation X) taking into account process parameters, such as stirring rate or 
homogenization set up and formulation parameters, such as amount of stabilizer used. 
Formulations were characterized regarding average hydrodynamic particle size, PDI and 
zeta potential. Based on the obtained results optimal parameters for the nanoparticle 
production were determined and included in the final preparation protocol. Based on this 
protocol, preparation methods for chitosan-coated (formulation CX) and PEI-coated 
(formulation PX) PNPs were established. Three final PNP formulations were prepared 
according to the established protocols and were thoroughly characterized.  
5.1. Uncoated PNPs 
Uncoated PNPs were prepared by an emulsion-diffusion-evaporation method, adopted 
from N. Nafee et al. (22). It was found that the stirring rate during formation of o/w 
emulsion, dilution of emulsion with water and evaporation of organic solvent influenced 
the particle size. As expected, at high stirring rate (450 rpm) smaller particle size was 
obtained. Different standard deviations of particle size for different stirring rates were 
probably a coincidence, as they did not show any special trend. However, the PDI was not 
affected by the stirring rate used and was comparable at high and low stirring rate. A study 
from M. Holzer et al. (32) reported that, compared to our uncoated PNPs, slightly smaller 
PNPs (i.e., < 200 nm) with similar PDI (i.e., < 0.15) could be produced, using slightly 
higher stirring rate (i.e. 500 rpm) compared to our preparation protocol. 
Next the impact of stabilizer amount (i.e., PVA) in the water phase was investigated, since 
previous studies have reported that higher concentration of PVA (i.e. 3-5% (w/v)) resulted 
in smaller particle sizes (26, 27, 28, 29). This is consistent with our study. By increasing 
the amount of PVA in water phase the size of the PNPs was reduced, but without any 
influence on the PDI. The decreased size with increasing amount of PVA is due to the fact 
that PVA acts as emulsifier in the formulation of PLGA nanoparticles (33). However, 
Sahoo et al. reported decreased cellular uptake of PNPs with high amount of adsorbed 
PVA (33). To circumvent this hurdle, a final concentration of 2.5% (w/v) PVA was 
chosen, which was the lower of two concentrations investigated in our study. Usage of 
narrow glass container instead of a beaker resulted in a decrease of both the hydrodynamic 
particle size and the PDI of PNP dispersion. 
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To study the long-term stability, formulation X was freeze-dried and stored at 2-8 °C up to 
2 months. The hydrodynamic particle size, PDI and zeta potential of re-dispersed freeze-
dried sample were comparable to the initial PNP formulation, thus the stability of freeze-
dried samples was confirmed. Study by M. Holzer et al. showed that uncoated PNPs could 
be re-dispersed after freeze-drying (32). However, the particle size and PDI in their study 
significantly increased. They used lower concentration of PVA (i.e., 1% (w/v)) compared 
to our study, which could influence on the re-dispersibility of PNPs after freeze-drying. As 
shown by T. Zelenková et al. PVA in PNP dispersion could act as a lyo-protectant in 
freeze-drying process by adsorbing onto the surface of nanoparticles and thus preventing 
aggregation of nanoparticles (34). This implies that the PVA concentration should be high 
enough: i) to stabilize emulsion during preparation of PNPs and concurrently, ii) to achieve 
lyoprotection during freeze-drying.  
Surface hydrophobicity of PNPs was investigated using a modified Rose Bengal assay, 
which was established in this work. Uncoated PNPs showed the highest hydrophobicity 
(i.e., the highest RBA value) and were even more hydrophobic than the respective PLGA 
powder. DSC curve of PLGA powder showed an endothermic peak at ~53 °C, which 
coincides with values from literature (i.e., 40 to 60 °C) (35). Formulation X showed a 
smaller endothermic peak compared to pure PLGA that was shifted towards lower 
temperatures due to nanoparticulate morphology, which increased the specific surface area 
(36). Similar peak shifts were observed also for the physical mixtures. The SEM images 
revealed that bridges between the spherical to square-like PNPs were formed, as previously 
published by M.Ø. Andersen et al. (37). The average particle sizes calculated based on the 
SEM images were slightly smaller than the sizes determined by PCS. This can be 
explained by the different nature of the samples used in both techniques. Thus, SEM shows 
PNPs in a dry state, while PCS measures particle size of PNPs in dispersion (38). Porous 
surface morphology of individual PNPs was observed, which could be assigned to the 5 
nm gold coating procedure. SEM also confirmed that the freeze-dried PNPs were covered 
with residual PVA. After a purification step, the excess PVA was not detected on SEM 
images.  
Cell interaction studies showed that uncoated PNPs interacted with human buccal TR 146 
epithelial cells and were internalized to a greater extent than the coated PNPs. It was 
reported by several research groups that coated PNPs with positive surface charge show 
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higher cellular uptake than uncoated PNPs (38, 39). In contrast, this phenomenon was not 
confirmed in our study.  
A major challenge in PNP development is the reproducibility of PNP preparation (8, 9). 
Thus, in our study preparation and characterization studies were repeated twice to evaluate 
the reproducibility of the preparation method with respect to characteristics of prepared 
PNPs. Results confirmed that the preparation of PNPs according to the developed protocol 
is reproducible, since the average hydrodynamic particle size, PDI, zeta potential and pH 
value of PNP dispersion were comparable between both repetitions. 
5.2. Chitosan-coated PNPs 
Results presented in our study demonstrated a correlation between chitosan amount in 
dispersion and characteristics of prepared PNPs. The increase in amount of chitosan led to 
an increase in average particle size, PDI and zeta potential. Higher amounts of chitosan led 
to increased viscosity of the aqueous phase, therefore, reduced homogenization efficiency, 
resulting in larger particles and higher PDI. Thus, the optimal amount of chitosan in the 
formulation was identified to be 12.5 mg. Compared to the uncoated PNPs, the chitosan-
coated PNPs showed 95 nm bigger particle size and ~35 mV higher zeta potential. The 
increase in particle size could be attributed to the thickness of the chitosan coating. The 
increase in the zeta potential could not be attributed solely to the chitosan adsorbed on the 
surface of PNPs, but could also result from the excess of chitosan in the dispersion, 
because PNP dispersions were not purified. Such high zeta potential values indicate 
stability of PNP dispersion. The pH value of formulation CX was adjusted to 5.5, to assure 
stability of prepared PNP dispersion (according to our preliminary studies) and to preserve 
the positive charge of chitosan (40). Compared to formulations X and PX, the preparation 
of formulation CX was not reproducible. This has been addressed previously in the 
literature (8, 9) and represents one of the major drawbacks of chitosan-coated PNPs. The 
dispersion of chitosan-coated nanoparticles was freeze-dried without addition of lyo-
protectants according to the protocol used for uncoated PNPs. The results showed that 
freeze-dried formulation CX could not be sufficiently re-dispersed. The use of appropriate 
(concentration) of lyo-protectants is essential for successful re-dispersion of freeze-dried 
chitosan-coated PNPs as reported previously (5, 12, 26, 34). The hydrodynamic particle 
size as well as the PDI increased, while the zeta potential of re-dispersed freeze-dried 
PNPs was only slightly lower compared to the value of initial PNP dispersion. These 
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properties of re-dispersed freeze-dried dispersion did not change over a time period of two 
months when stored at 2-8 °C. Future studies should focus on the adjustment of the PVA 
concentration or addition of other known lyoprotectants such as glucose, sucrose, 
trehalose, mannitol, dextran, PVP, etc. to achieve efficient re-dispersibility of PNPs after 
freeze-drying (5, 12, 34).  
Concerning the hydrophobicity studies, the chitosan coating caused a red shift of the 
absorption maximum of RB, so the use of a correction factor was necessary in the 
calculations of the Rose Bengal assay results. This phenomenon has been mentioned by 
several research groups, but not addressed in details (16, 23). The correction factor was 
shown to be appropriate for managing the red shift. It was used in calculation of the final 
results of the assay. As expected, formulation CX was more hydrophilic (i.e. lower RBA 
value) than formulation X (or PLGA powder) due to the hydrophilic characteristics of 
chitosan coating. Line in Scatchard plot for formulation CX showed a positive slope, 
giving negative theoretical parameters, which suggests that chitosan-coated PNPs were the 
most hydrophilic PNPs prepared in our work. This property could be advantageous in 
prolonging blood-circulation time, as they might escape from RES (13, 14). Importantly, 
the results of the Rose Bengal assay should be interpreted with respect to the possible 
interference due to electrostatic interactions (16). Positively charged particles might 
interact with the negatively charged Rose Bengal dye leading to higher results as they 
should be. 
The viscosity of chitosan-coated PNP dispersion was slightly lower than the viscosity of 
the pure chitosan solution, both showing shear thinning properties. Due to adsorption of 
chitosan on the surface of PNPs, less residual (free) chitosan was available in the 
dispersion, which resulted in decreased viscosity of PNP dispersion compared to pure 
chitosan solution. Storage modulus (G`) of formulation CX was measured also at low 
angular frequencies, which was not possible in case of formulation X. It could not be 
measured until an angular frequency of at least 0.4 rad/s was applied. This leads to the 
conclusion that coated PNPs interacted due to chitosan on their surface. The SEM images 
of the freeze-dried chitosan-coated PNPs revealed additional material present between 
PNPs that could be attributed to the residual chitosan (and PVA). And additionally, a 
network between PNPs, which was observed by SEM imaging, could be also attributed to 
this residual (free) chitosan. 
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Formulation CX showed smaller endothermic peak, shifted towards lower temperatures 
compared to the peak on DSC curve of PLGA powder, which was due to decreased particle 
size and increased specific surface area after nanoparticle formation, as described already 
for uncoated PNPs (36). 
Concerning cellular interactions, available literature has reported interactions and cell 
uptake of positively charged nanoparticles (38, 39). This is partly in line with our results 
obtained with human buccal TR 146 epithelial cells. The positively charged chitosan-
coated PNPs showed interactions with the cell membranes, but the cell uptake was limited. 
Regarding this result PNPs as formulation CX are not appropriate carriers for intracellular 
drug delivery. The observed interactions can be attributed to the mucoadhesive properties 
of chitosan (41, 42). The cationic polymer of PNPs can interact with the negatively 
charged glycoproteins in the cell glycocalix and the mucus layer (22). Moreover, several 
other advantages, such as (i) decreased initial burst release of incorporated drug, (ii) 
increased stability of incorporated drug and (iii) possibility to conjugate targeting ligands 
to free amine groups make chitosan an interesting candidate for surface modification of 
PNPs (38, 39).  
5.3. PEI-coated PNPs 
The results showed that bigger amounts of PEI in water phase led to smaller average 
particle size without affecting PDI and zeta potential. Similar to chitosan, higher PEI 
concentrations resulted in increased viscosity of water phase and inefficient 
homogenization during preparation of PNPs.  
The particle sizes of formulation PX were smaller than formulation CX, but larger than 
formulation X. The prepared PEI-coated PNPs showed 35 nm bigger particle size and 
~15 mV higher zeta potential compared to uncoated PNPs. The zeta potential was positive, 
but lower than in case of the chitosan coated PNPs. Similar as in the case of the chitosan-
coated PNPs, this increase in zeta potential could not be attributed to the PEI adsorbed on 
the surface of PNPs only, but also to the excess of PEI in the dispersion of non-purified 
PNPs. The PDI of formulation PX was two-fold higher compared to PDI of formulation X. 
The freeze-dried formulation PX (without the addition of any lyoprotectant) showed 
similar behaviour than formulation X. The PNPs were readily re-dispersible and their 
properties did not change compared to initial PNP dispersion, which has not been 
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described in literature yet (31, 34). The stability study revealed that freeze-dried PNPs 
were stable over a time period of two months at 2-8 °C, regarding their characteristics after 
re-dispersion. 
The hydrophobicity of formulation PX was classified as high (i.e., RBA value 29.00 µg/mg 
compared to 44.55 µg/mg for formulation X and 0.21 µg/mg for formulation CX). A red 
shift of the absorption maximum was detected and thus, the correction factor was applied 
and was shown to be appropriate for calculation of assay’s results. Although electrostatic 
interactions between positively charged PEI-coated PNPs and negatively charged RB could 
take place (16), the hydrophobicity was still higher than expected. Since PEI has a negative 
RBA value (even more negative than chitosan), we expected that the PEI-coated PNPs 
would show the most hydrophilic characteristics among all investigated formulations. 
However, the data were more comparable with hydrophobic uncoated PNPs. This suggests 
that PEI did not sufficiently adhere to the particle surface, what was further confirmed by 
the rheology studies. Formulation PX showed a similar behaviour as the pure PEI solution 
in respect to viscosity and storage modulus. This indicates that most of the PEI was present 
in the dispersion medium and did not adhere to the PNP surface. The storage modulus 
could not be measured at angular frequencies smaller than 0.439 rad/s, since PNPs coated 
with PEI did not form interactions as chitosan-coated PNPs. The SEM images showed that 
morphology of formulation PX was more similar to formulation X than to formulation CX. 
As expected, additional material besides PNPs was visible on the SEM images of freeze-
dried PEI-coated PNPs. SEM images of purified formulation PX (captured at high 
magnification) revealed some porous structures, which could be attributed to self-
assembled structures of excess free PEI and PVA in the water phase. This was confirmed 
by additional experiment where PEI/ PVA water solution was homogenized. The resulting 
dispersion contained porous structures with diameter of ~300 nm. DSC measurements 
showed similar results for formulations X and CX. The shift of the endothermic peak 
observed in case of formulation PX compared to pure PLGA polymer was probably due to 
particle size reduction, which has already been discussed in the previous chapters (5.1. and 
5.2.). 
The cell interaction studies supported our assumption that the PEI-coating of PNPs was not 
efficient. No PEI-coated PNPs were internalized by the human buccal TR 146 epithelial 
cells and only a few PNPs were located at the outer cell membranes. Due to positively 
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charged surface of PEI-coated PNPs, interactions with the cell membranes took place, 
which has been also described in the literature (38, 39). Contrary to formulation CX, the 
formulation PX showed a non-functional coating, resulting in weak interactions with the 
cell membranes. Thus PEI-coated PNPs were washed away after their incubation with the 
cells. 
We assume that the main reason for the inefficient coating is that PEI favours interactions 
with the water phase and not with the PLGA surface of nanoparticles. Consequently, PEI 
did not coat the nanoparticle surface, but rather stayed in the water phase. On the other 
hand M. Bivas-Benita et al. (30) successfully prepared PEI-coated PNPs, using a slightly 
different method of preparation. First, PLGA was dissolved in dichloromethane and PEI in 
acetone and an organic phase was formed, combining both solutions. This phase was later 
mixed with the water phase with stabilizer. A similar procedure was described by H. Katas 
el al. (31), who also reported about efficient PEI-coating of PNPs. The difference of these 
two preparation protocols compared to our protocol is that in our study PEI was added 
directly into the water phase with the stabilizer, whereas in previous studies PEI was 
dissolved in organic phase. Due to the issues mentioned above, no efficient coating was 
achieved with our preparation protocol. However, the preparation of PEI-coated PNPs 
according to the developed protocol was reproducible. 
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6. Conclusions 
The proposed preparation protocol for non-functionalized (i.e., uncoated) PNPs enabled 
the production of nanoparticles with reproducible characteristics, namely average 
hydrodynamic particle size ~230 nm, zeta potential ~-5 mV and PDI ~0.08. Coating of 
PNPs using chitosan revealed a stable coating-layer, which was estimated to be ~ 95 nm 
thick, whereas the PEI-coating was less successful, with thickness of ~35 nm. Both 
formulations had a positive zeta potential (+30 mV and +10 mV, respectively) 
compared to uncoated PNPs, indicating presence of positively charged polymers on PNP 
surface.  
The PEI-coated PNP dispersion showed similar rheology to pure PEI solution in contrast to 
chitosan-coated PNP dispersion, which showed a different rheological profile than pure 
chitosan solution, indicating that PEI was free in dispersion, i.e. not adhered to the surface 
of PNPs. The hydrophobicity of uncoated and PEI-coated PNPs was shown to be 
comparable, whereas the surface of chitosan-coated PNPs was less hydrophobic. The 
prepared PNPs showed spherical to square-like morphology with bridges between them, 
which were more evident in case of chitosan-coated PNPs. In case of purified PEI-coated 
PNPs some porous structures were observed, which could be attributed to PVA/PEI self-
assembly. All PNP formulations prepared in scope of this study had a similar endothermic 
peak as pure PLGA, but shifted to lower temperatures. All freeze-dried PNP formulations 
were stable up to 2 months when stored at 2-8 °C. Chitosan-coated PNPs were poorly re-
dispersible after freeze drying, which resulted in bigger average particle sizes and higher 
PDI. 
Finally, cell interaction studies showed that uncoated, slightly negatively charged, PNPs 
were taken up by the human buccal TR 146 epithelial cells. Positively charged chitosan-
coated PNPs interacted with the outer cell membrane and were internalized to minor 
extent, while PEI-coated PNPs showed only weak interactions with the outer cell 
membrane and did not enter the cells. 
To sum up, this study presents the first step in the establishment of a standardized protocol 
for production of promising nanocarriers for both systemic and topical drug delivery. 
Preparation protocols for uncoated and chitosan-coated PNPs were successfully developed, 
while preparation protocol for PEI-coated PNPs needs to be further adapted to achieve 
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efficient coating. While uncoated and PEI-coated PNPs were efficiently freeze-dried 
without the use of additional lyo- or/and cryoprotectants, the use of such excipients should 
be further investigated to optimize the freeze-drying process of chitosan-coated PNPs. 
Overall; the results presented in scope of this thesis provide some new insights into the 
structure, characteristics and behaviour of PNPs. Moreover, a modified Rose Bengal assay 
(with the use of correction factor for the red shift of RB absorption maximum) was 
developed, which might be used for determination of nanoparticle surface hydrophobicity. 
Surface functionalization of PNPs with positively charged polymers, such as chitosan and 
PEI, which are known to have mucus penetrating characteristics, might result in mucus 
penetrating properties of coated PNPs. However, some additional studies should be 
conducted, such as evaluation of stability under different storage conditions and in 
different forms (e.g., dispersions, freeze-dried formulations), purification of PNP 
dispersions, determination of drug loading capacity and drug release profile, additional cell 
interaction studies using different cell types, as well as determination of mucus penetrating 
properties, to bring PNP formulations closer to clinical practice. 
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